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 ABSTRACT 
The impact of post translational modification on the aggregation of the ß-amyloid peptide 
in the presence or absence of lipids 
 
 Albert Walton Pilkington IV 
Alzheimer’s disease (AD) is a neurodegenerative condition afflicting 5.7 million 
Americans with no effective treatments. The pathology of AD is described by the formation of 
neurotoxic oligomers formed by the self-assembly of amyloid-β (Aβ). The affinity of oligomers 
for cellular membranes disrupts calcium homeostasis and is believed to be the underlying cause 
of neurotoxicity; however, due to the metastability of oligomers, it has been difficult to 
understand their role in membrane interactions and self-assembly. Here we utilize post 
translational modifications (PTM) to understand the role of specific amino acids on Aβ40-
membrane interactions and self-assembly. We employ ThT, AFM, CD, and polydiacetylene 
assays (PDA) to determine how PTMs of Met35, Lys28, and Lys16 affect the aggregation rates, 
population distributions, morphologies, and secondary structure of Aβ40 in the presence or 
absence of a model membrane system, total brain lipid extract (TBLE). Our results show that 
oxidative environments promote the selective oxidation of Met35 (Met35[O]). Decreases in the 
magnitude of Aβ40 aggregation was observed along with an inhibition of oligomer structural 
transitions to fibrils. In the presence of total brain lipid extracts (TBLE), Met35[O] showed 
increased aggregation rates relative to Aβ40 and reduced peptide-membrane interactions. 
Isolation of oxidative effects on TBLE and Aβ40 showed that the oxidation of the membrane was 
responsible for reductions in peptide-membrane interactions. Subsequent studies chemically 
acetylated Lys16 and Lys28 to understand how the removal of lysine’s cationic properties alters 
Aβ self-assembly and membrane-binding. Here we report that lower levels of acetylation, 
predominantly affecting Lys16, reduced fibrilization and oligomerization of Aβ40 while higher 
levels of acetylation affecting both Lys16 and Lys28 dramatically inhibited fibril formation and 
reduced oligomerization. In the presence of TBLE, aggregation of Aβ40 was observed even under 
higher levels of acetylation. Under the influence of the membrane, fibril aggregates of Aβ40 were 
observed with higher levels of acetylation producing annular aggregates suggesting the 
promotion of secondary aggregation pathways. Additionally, the magnitude of the peptide-
membrane interactions of acetylated Aβ and PDA/TBLE vesicles were reduced but not absent. 
Collectively, these results highlight the role specific amino acids play in the assembly of Aβ, and 
how the presence of membranes modulates peptide-membrane interactions and influence 
aggregation pathways 
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1. Introduction: Mutations, modifications, and the membrane’s role in the 
aggregation of Aβ associated with Alzheimer’s disease  
Alzheimer’s disease (AD) is characterized by the accumulation and deposition of 
fibrillar aggregates of the amyloid- (A) peptide into neuritic plaques. These amyloid deposits 
were thought to play a central role in AD; however, the correlation between plaque load and 
disease is weak. Increasing evidence supports the notion that a variety of small, globular 
aggregates of A, referred to broadly as A oligomers (AO), may in fact be the primary 
culprits associated with neurotoxicity. The aggregation of Aβ proceeds via a nucleation-
dependent polymerization mechanism that is heavily influenced by changes in peptide 
sequence, environmental conditions, and preparatory steps. Familial point mutations of Aβ 
produce the early onset of Alzheimer’s disease but only account for a small fraction of the 
number of AD cases. Recently, the analysis of sporadic AD patient’s cerebrospinal fluid 
revealed the presence of post-translationally modified forms of Aβ and may represent changes to 
the physiochemical properties of Aβ that promote secondary aggregation pathways and toxic 
mechanisms. Experimental evidence shows AD patients exhibit altered membrane compositions. 
The presence of membrane surfaces also possesses the ability to modulate the aggregation of Aβ, 
stabilize toxic intermediates such as AβOs, and are themselves targets of Aβ’s toxicity. 
Ultimately, understanding the interplay between Aβ and membranes, with respect to direct 
effects on Aβ sequence, modification, and environmental factors is important in elucidating the 
underlying causes of Alzheimer’s disease. 
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1.1 Alzheimer’s Disease  
Alzheimer’s disease (AD) is a fatal neurodegenerative disorder that is the most prevalent 
form of dementia. Neuropathological and neurochemical hallmarks of AD include: synaptic loss 
and selective neuronal cell death; decreases in markers for certain neurotransmitters; and 
abnormalities in neurons and their processes as well as in the extracellular space. Two of the 
main features associated with AD are neurofibrillary tangles comprised of the protein tau and 
cerebrovascular, diffuse, and neuritic plaques composed predominantly of the amyloidogenic 
peptide amyloid-β (Aβ). These proteinaceous deposits of tau and A consist of stable amyloid 
fibrils, which are -sheet rich fibrous protein aggregates. Similar deposition of amyloid is 
associated with numerous other diseases.1 
In the early 90’s, the amyloid cascade hypothesis was introduced, which postulated that Aβ 
aggregation and deposition directly lead to neuronal death, resulting in AD.2 Yet, the correlation 
between plaques and cognitive dysfunction in AD has been questionable for years,3–7 and with 
Aβ-directed therapeutic strategies failing in numerous clinical trials, the role of A in AD 
progression is being re-evaluated.8–11 This has led to an enhanced research focus on diffuse, 
soluble aggregates of Aβ. Various small, globular aggregates of A, referred to broadly as A 
oligomers (AO), were detected in AD patients a few decades ago,12–14 and these AO were 
originally classified as being intermediates toward the formation of amyloid fibrils. Over the 
years, increasing evidence points toward AOs playing a central role in AD, as AOs correlate 
more strongly with AD progression in patients and animal models.15–19 For example, AO 
formation and buildup occurs early compared with plaque buildup (much earlier than plaque 
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deposition) in the AD brain20–22 and CSF,23 which has led to extensive efforts to develop assays 
to detect AOs for potential application as biomarkers.24–31  
 An extensive body of evidence has linked high levels of AβOs in the brain to a variety of 
pathogenic consequences associated with AD (summarized in Table 1). As such, there has been 
significant effort made to characterize AβO formation, structure, and biochemical/biophysical 
characteristics (such as interactions with other proteins and lipids) in the hope that underlying 
modes of AβO-related toxicity could be revealed.32–37  
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Table 1.1: Toxic mechanisms associated with AβOs. 
Toxic effects of AβOs Model System References 
Reduction in neural plasticity 
 
mice, rat 37–40 
Stimulation of tau phosphorylation cortical neurons (rat), hippocampal neurons, 
neuroblastoma, primary neurons, Tg-Mice 
41–45 
Choline acetyltransferase Inhibition 
 
cholinergic cell lines 46,47 
Oxidative stress 
 
cortical neurons, hippocampal neurons, in vitro, 
neuroblastoma, 
48–51 
Endoplasmic reticulum stress 
 
cortical astrocytes, cortical neurons (rat), 
fibroblasts, Tg-mice 
45,52,53 
Receptor disturbance 
 
cortical neurons, hippocampal neurons 54–57 
Insulin resistance 
 
cortical neurons, hippocampal neurons, rat  42,57–59 
Synapse deterioration 
 
hippocampal neurons, pyramidal neurons (rat), Tg-
mice, 
21,35,56,60 
Axonal transport 
 
cortical neurons, hippocampal, in vitro, Tg-mice 61–64 
Astrocytes/microglia effects 
 
cortical astrocytes, Tg-mice 43,53,65,66 
Cell cycle disruption 
 
cortical neurons, Tg-mice, 67,68 
Selective neuron death 
 
mice 39,69 
Inhibition of long-term potentiation 
 
mice 37,40 
Calcium dysregulation 
 
cortical neurons (rat), hippocampal neurons, 
primary neurons 
44,45,51,53 
Modulation of metal toxicity 
 
neuroblastoma 48 
Cytoskeleton disruption 
 
primary neurons 49 
Modulation of Receptor/Channel 
Activity 
 
hippocampal neurons 51 
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1.2 The Aβ Peptide 
Aβ is an approximately 4 kDA peptide (typically 40–42 amino acids long) that is derived 
from the transmembrane portion of the amyloid precursor protein (APP; Figure 1). The 
production of Aβ is achieved by the sequential cleavage of APP by two membrane-bound 
endoprotease activities, β- and γ-secretase. The two predominant Aβ peptides produced are 40 
and 42 amino acids in length, and these peptides are referred to as Aβ40 and Aβ42 respectively. 
Aβ is amphipathic in nature (having a predominately hydrophilic N-terminus and a 
predominately hydrophobic C-terminus), which is thought to drive its aggregation. As the C-
terminal end of Aβ coincides with the transmembrane portion of APP, Aβ42 has a larger 
hydrophobic domain, making it more fibrillogenic compared to Aβ40 and deposits to a much 
greater extent in the brain.70–72 Only about 10% of APP is processed via this Aβ producing 
pathway. Most APP is cleaved by the α-secretase, generating a series of much more benign 
peptide fragments. 
The hydrophilic N-terminal region of Aβ can adopt both an α-helical or β-sheet structure 
dependent on solution conditions, for example pH.73,74 The hydrophobic C-terminal end of Aβ 
has a propensity to adopt β-sheet structure upon aggregation independent of solvent conditions.73,74 
Beyond its amphipathic nature, several other domains have been identified in Aβ. The different 
polymorphic fibril structures of Aβ are comprised of bundled β-sheets with backbones 
orthogonal to the fiber axis creating a cross-β structure,75 and two β-strand forming domains 
(residues 11–21 and 29–39 respectively) that are separated by a turn/bend region (around 
residues 23–26) identified through various experimental and computational studies.76–79 The central 
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region of Aβ (residues 16–21), contained within one of the β-strands, has enhanced amyloidogenic 
properties and represents a hydrophobic core.80 
 
Figure 1.1 APP processing and subsequent Aβ amino acid sequence with specific 
domains of interest specified. Proteolytic cleavage of APP is initiated at residue 671 
by β-secretase followed by either non-amyloidogenic processing, cleavage at residue 
687 by α-secretase, or amyloidogenic processing, cleavage at residue 711, 713, 714, 
or 726 by γ- secretase. The amino acid sequence below highlights the region of APP 
from which A is produced with the numbering referring the residues in A. The 
orange highlighted region represents the intact Aβ42 sequence. Hydropathy indexes 
of individual residues are color coded according to hydrophobic (blue), slightly 
hydrophobic (light green), and hydrophilic (red). Regions of interest and cites of 
secretase activity within the APP and A are indicated. 
1.3 Aβ aggregation—a complex mechanism 
The aggregation of Aβ (and other amyloid-forming proteins) is typically characterized in 
terms of fibril formation (Figure 1.2). Aβ fibril formation occurs via a complex aggregation 
pathway. Fundamentally, AβOs can be subdivided into species that are intermediates in fibrils 
formation (referred to as being on pathway) or species that do not directly lead to fibrils (referred 
to as being off pathway). This is a contributing factor to the immense heterogeneity observed in 
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AβO populations as will be discussed in more detail later. In general, amyloid formation 
proceeds via a nucleation dependent polymerization mechanism (Figure 1.3).81–83 With this 
mechanism, aggregation initially occurs via a slow nucleation phase (often called the lag phase) 
that involves the formation of a thermodynamically unfavorable critical nucleus that is associated 
with a transition from a native to non-native protein conformation. For Aβ, the critical nucleus is 
likely a multimeric species.84–86 Once the critical nucleus has formed, an elongation or growth 
phase (characterized by a relatively rapid extension of fibril aggregates) occurs. While numerical 
models can extract important parameters (lag phase times, elongation rates, critical nucleus size) 
from experimental data,87 the actual aggregation pathway toward fibrils can be complicated. For 
example, other on pathway intermediates, like protofibrils, are also observed in Aβ aggregation. 
Protofibrils are amyloid-like, elongated aggregates with filament-like morphologies and are late-
stage intermediate precursors on the aggregation pathway to fibrils. A key aspect that facilitates 
on and off pathway aggregation routes and complicates investigations of AβOs is that they 
possess structural plasticity and are metastable and transient in nature. 
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Figure 1.2. Production and aggregation of Aβ. Aβ is a cleavage product of APP, a 
transmembrane protein. Monomeric Aβ transitions between ordered and disordered states. Once 
dimerization occurs, subsequent aggregation occurs either on pathway or off pathway with respect 
to fibril formation. The aggregates associated with these different pathways increase in molecular 
weight from the left to the right of the schematic. Fibrillization can proceed via several potential 
pathways that can populate various intermediate aggregate states, including oligomers and 
protofibrils. Off-pathway oligomers of various size may also form. Annular aggregates of Aβ can 
also form and are thought to potentially be associated with forming pore-like structures. 
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Figure 1.3. Aggregation of Aβ via nucleation-dependent polymerization. The thioflavin-T (ThT) curve is 
representative of the aggregation of Aβ toward fibril aggregates. This sigmoidal curve is defined by three 
distinct regions First, the initial lag-phase (green) is defined by the formation of LMW AβOs and HMW AβOs 
as Aβ forms the critical nucleus necessary for fibrillization. Aggerate species generated during the lag-phase 
are ThT-negative. Second, upon formation of the critical nucleus fibril formation is initiated and the 
elongation phase of the curve begins. This elongation/growth phase (pink) is dominated by a mixture of 
HMWAβOs which are ThT-negative, and to a greater extent small ThT-positive protofibril structures. Third, 
as the protofibrils increase in size and associate to form mature fibrils and plaques the ThT signal ultimately 
reaches a plateau (blue).   
 
Further complicating the issue is the observation that A can aggregate into a variety of 
morphologically distinct fibril structures, referred to as polymorphs.88–92 This phenomenon is 
predicated on subtle changes of environmental conditions associated with aggregation, and as a 
result, preparatory protocols employed in experiments determines the resulting A fibril 
morphology.89 While polymorphic aggregates are readily observed within in vitro studies using 
synthetic Aβ, polymorphic structures have been observed in amyloids derived from tissue, and it 
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is thought that variations in A aggregate morphologies may play an important role in AD.93,94 
For example, polymorphic aggregates and fibrils may result in distinct biological activities and 
levels of toxicity that could underlie variations in AD,78 and distinct fibril structures can be 
directly associated with individual AD patients and clinical phenotype.95,96  
A complicating factor in evaluating and comparing studies aimed at elucidating Aβ 
formation, structure, and physiological impact is divergent experimental conditions, such as Aβ 
preparation protocols, heavily influences experimental outcomes. In terms of oligomers, the 
emergence of distinct fibril structure strongly suggests that there would also be distinct 
oligomeric precursors associated with their formation. Indeed, distinct AβO species can be 
observed within in vitro aggregation assays under conditions that result in fibril polymorphs 
(Figure 1.4).97 For studies conducted with synthetic peptide, there are a variety of protocols used 
to solubilize A (Table 1.2). Typically, these protocols consist of a disaggregation step and a 
reconstitution step. The disaggregation steps usually involve the use of hydrogen bond disrupting 
solvents, i.e., hexafluoroisopropanol (HFIP) or trifluoroacetic acid (TFA), that break down pre-
existing aggregates within lyophilized stocks of A. These solvents are often removed under 
vacuum, leaving a peptide film. The reconstitution step involves dissolving these peptide films 
into a solvent that facilitates dilution into an appropriate buffer. Dimethyl sulfoxide (DMSO) is 
often used, creating a concentrated stock that is diluted into the desired buffer. Disaggregation 
and reconstitution can also be facilitated by changes in pH. Sometimes reconstitution is 
performed directly into the final buffer. Importantly, variations in preparatory protocols indeed result 
in different populations of oligomers (Table 1.2 and Figure 1.4), and these variations can 
complicate direct comparisons between different reports within the literature. Further 
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complicating the issue, there are often distinctions observed between studies performed with 
synthetic A and naturally derived A.98 In many studies aimed at elucidating activity of AβOs, 
specific preparations are used to obtain a particular population of oligomer species. These are 
then directly applied to different model systems, ranging from cell culture to animal models. 
However, there is often a lack of effort to verify that once added to the model system (which can 
often be a pronounced change in chemical environment) that these AβO species do not dissociate 
or aggregate into a different AβO or Aβ aggregates. To truly relate specific AβOs to a neurotoxic 
activity, effort should be invoked to attempt additional controls of this type. 
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Table 1.2. Representative disaggregation, reconstitution, and miscellaneous 
protocols for the preparation of Aβ and observed AβOs. 
Classification Disaggregation Reconstitution Miscellaneous Result References 
ADDLs None 
F12 Media 4 
℃ 
Centrifuged 14,000 
×g for 10 mins 
5–6 nm by 
AFM 
(height) 
39 
ADDLs HFIP 
DMSO at 5 
mM Aβ 
Sonicate 5 mins, 
dilute with 
DMEM/F12 Media 
A11+ 99 
Globulomers HFIP 
DMSO at 5 
mM Aβ 
Sonicate 10 mins, 
dilute PBS + 0.05% 
SDS 
16–56 kDa 
by SDS-
PAGE 
100 
Globulomers HFIP 
DMSO at 5 
mM Aβ 
Dilute PBS + 0.05% 
SDS, Dialyze 
38–48 kDa 
by SDS-
PAGE 
101 
Aβ*56 HFIP 
DMSO at 5 
mM Aβ 
Sonicate 20 min, 
PBS + 0.2% SDS 
incubate 6 h, dilute 
and incubated 18 h; 
centrifuge 3000 ×g, 
dialysis 
56 kDa by 
Native-
PAGE 
102 
AβOs HFIP DMSO 
F12 Media incubated 
at 4 ℃ for 24 h 
1–4 nm by 
AFM 
103,104 
AβOs HFIP/NH4OH 
10 mM Tris-
HCl 
Addition of Zn2+ 
10–12 nm 
by AFM 
99 
AβOs 
TFA/HFIP 
(2Xs) 
2 mM NaOH 
PBS Centrifuge 
386,000 ×g 
2.5 nm by 
AFM 
89,97 
AβOs 
TFA salt/2 
mM NaOH, 
pH ~10.5, 1 
min sonication 
PBS - 
3–12 nm by 
AFM  
105 
AβOs 
10% NH4OH 
(w/v) 
sonicated 5 
mins, 
lyophilized 
60 mM NaOH - 
1–10 nm by 
DLS 
106 
AβOs LMW - DMSO 
Sonicate 1 min, 
centrifuge 16,000 ×g, 
SEC, PBS, PICUP 
crosslinking 
4–26 kDa 
by SDS-
PAGE 
107 
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Figure 1.4. Heterogeneity of AβOs. A series of atomic force microscopy images and 
size analysis, i.e. height histograms, of AβOs formed from synthetic Aβ that had been 
prepared by some of the protocols described in Table 2. The AβOs were prepared in 
the following way: (A) protocol provided in the AggreSure β-amyloid kits available 
from AnaSpec which consists of a reconstitution step directly into Tris buffer with 
bath sonication; (B) 10% NH4OH disaggregation buffer, followed by additional 
treatment with HFIP, and reconstitution in 2 mM NaOH (pH > 11) with subsequent 
dilution into Tris buffer; (C) 10% NH4OH disaggregation buffer, and 
reconstitution in 60 mM NaOH (pH > 11) with subsequent dilution into HEPES 
buffer; (D) HFIP disaggregation, reconstitution in DMSO, followed by dilution into 
PBS; (E) TFA disaggregation with sonication, an additional HFIP disaggregation step, 
reconstitution with NaOH, and dilution into PBS; (F) No disaggregation step and 
direct reconstitution in to phosphate buffer. 
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1.4 Familial Mutations and Post-Translational Modification of Aβ 
A number of mutations within Aβ are associated with Familial forms of Alzheimer’s 
disease (FAD), which are often characterized by early onset or other variations in disease 
progression. FAD mutations consist of single point mutations in the amino acid sequence of Aβ 
and produced a variety of AD symptoms including seizures, cardiovascular degradation, and 
cerebral amyloid angiopathy.108 Primarily, FAD mutations of Aβ are located within the turn 
region and central hydrophobic core of Aβ (E22Q Dutch, E22K Italian, D23N Iowa, E22G 
Arctic,) which promote increased aggregation and stabilization of unique aggregate species 
(Figure 1.5). Additionally FAD mutations within the N-terminal region (English H6R, Tottori 
D7N) or C-terminal region (Piedmont L34V) also promote the accelerated fibril formation of 
Aβ.108 For the FAD mutations mentioned above, the disease outcomes are principally associated 
with increased Aβ aggregation as APP processing remains unchanged. Additionally, some point 
mutations within A slow A aggregation (A21G Flemish and K16N) and instead promote 
increased secretion of Aβ resulting in early onset of AD.108 Some FADs are associated with 
altered APP processing, such as increased production of A or promoting A42 over A40. 
FADs, however, only make up 5% of the total cases of AD and do not explain the other 95% of 
sporadic Alzheimer’s disease (sAD) cases.109 Collectively, the ability of single point mutations to 
modify the A aggregation process and resulting aggregate structures demonstrates that single 
amino acids within the peptide can heavily influence aggregation. 
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Figure 1.5. Genetic mutations and post translational modifications of the Aβ 
sequence. Familial mutations and post translation modifications of the Aβ amino acid sequence, 
highlighted in orange, within APP. Familial mutations are represented below the Aβ sequence 
with mutations that increase aggregation of Aβ colored red and mutations that slow aggregation 
highlighted in blue. Familial mutations that are responsible for increased production of Aβ are 
denoted with an asterisk. Located above the Aβ sequence are the post-translational modifications 
of Aβ with arrows denoting the location and type of modification. Hydropathy indexes of 
individual residues are color coded according to hydrophobic (blue), slightly hydrophobic (light 
green), and hydrophilic (red). Familial and post translational modifications of Aβ shown here are 
not inclusive. 
Aging is known to be the largest risk factor of Alzheimer’s disease. The deregulation of 
cellular mechanisms governing post-translationally modified (PTMs) is also modified with 
increases in age.110–112 Analysis of sAD patient’s senile plaques and cerebrospinal fluid (CSF) 
shows that Aβ is post-translationally modified.113 Whether PTMs of Aβ are directly responsible 
for the initiation of the amyloid cascade is still unclear; however, aggregation of tau has been 
directly linked its hyperphosphorylation. Post translational modifications of Aβ involve 
phosphorylation, oxidation, pyroglutamination, deamidation, and citrullination. A number of 
these modifications directly influence the A aggregation process and resulting aggregate 
species. 
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Phosphorylation of Aβ in vivo occurs primarily at serine-8 and 26.114–116 Specifically, 
phosphorylation of Aβ at serine-8 is known to accelerate aggregation and promote 
oligomerization.114 Phosphorylated Aβ also exhibits increased toxicity in Drosophila models, 
and is found within the core of senile plaques suggesting its involvement in the early stages of 
aggregation.114 Pyroglutamination of Aβ (AβpE3-40/42) involves the removal of two N-terminal 
amino acids, aspartic acid-1 and alanine-2, in the Aβ sequence. This truncation is followed by the 
dehydration and cyclization of the new N-terminus of Aβ by the enzyme glutaminyl cyclase.117 
This change in the N-terminal charge state of Aβ creates a peptide that is more hydrophobic and 
therefore AβpE3-40/42 produces persistent oligomeric aggregates with increased rates of fibril 
formation.118,119 Furthermore, analysis of CSF in sAD patients revealed that the ratio of AβpE3-
40/42 to Aβ40/Aβ42 is increased suggesting pyroglutamination plays a role in late onset 
Alzheimer’s disease.113 These observations further indicate that changes in the A peptide at the 
single amino acid level can have a profound impact on the aggregation process, and hence AD. 
Aβ can also undergo PTMs that are more frequently associated with the aging 
process.120,121 Oxidation of Aβ via reactive oxygen species (ROS) occurs primarily at metionine-
35, in the absence of metals,122–125 and the modification of the hydrophobic methionine to a 
hydrophilic residue within the C-terminus region is suggested to reduce toxicity.126–128 
Interestingly, further oxidation from the sulfoxide to sulfone derivative of methionine restores 
toxicity, providing evidence of the fine line between toxic and nontoxic forms of Aβ.127 
Additional evidence has implicated methionine in initiating radical chain reactions within 
cellular membranes leading to increased lipid peroxidation and the formation of ion-channel-like 
structures within the membrane.129–131 The increased lipid peroxidation appears to create a 
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feedback loop in which lipid peroxidation products like 4-hydroxy-2-nonenal (HNE) can PTM 
Aβ forming Aβ-HNE adduct which have an increased affinity for cellular membranes.132 
Deamidation and citrullination are PTMs that have also been suggested to be affected by 
the aging process.120 Deamidation, involving the transition of an amide to a carboxylic acid, 
within Aβ results in the generation of a negative charge upon replacing asparagine-27 with 
aspartic acid via chemical modification. This deamidation significantly reduces the rate of fibril 
formation and promotes stable oligomeric intermediates of Aβ40/42 with an antiparallel β-sheet 
structure which has been postulated to be a toxic conformation of AβO.133 Citrullination of Aβ, 
involving the conversion of arginine-3 to an amide functional group, showed a marked reduction 
in fibrillization of Aβ40 but not for Aβ42.133 Citrullinated Aβ forms oligomeric and fibril 
structures, but was suggested to have alter β-sheet characteristic associated with fibril formation. 
Further analysis of AD brains reveals that citrullinated forms of Aβ are also localized within 
amyloid plaques.134,135 Collectively, point mutations of FADs and the PTM of Aβ found in sAD 
patients helps to illustrate the significant role that individual amino acids can play in aggregation, 
structure, and toxicity of Aβ.  
1.5 The influence of membranes on Aβ aggregation 
As previously discussed, Aβ aggregation is highly susceptible to sample preparation and 
environmental factors. While variations in sample preparation produce distinct polymorphs,89 the 
presence of surfaces also modulates aggregate morphology. For example, A aggregates into  
linear nanowires along the underlying lattice structure of graphite, and aggregation on mica 
yields AβOs that coalesce into protofibrils.136 In a physiological context, protein structure and 
dynamics are altered in the presence of a two-dimensional liquid environment provided by the 
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presence of lipid bilayers. The importance of studying the relationship between Aβ and 
membranes lies in the fact that the membrane compositions are altered in AD patients,137,138  
plasma membrane damage occurs in AD,139–141 and the binding of A to the plasma membrane is 
highly correlated with cell death.41,142  
 The interaction of Aβ with lipid membranes has been well established;143,144 however, the 
nature of the peptide-membrane interactions is complex, as subtle changes in physiochemical 
properties of the peptide or membrane can greatly influence their interactions. The initial 
interaction of Aβ with membranes involves the insertion of Aβ into the hydrophobic region of 
the membrane or the adhesion of Aβ to the membrane surface. Numerous research efforts 
suggest that the mechanism by which Aβ binds to membranes is driven by electrostatic and 
hydrophobic interactions between the peptide and membrane (see review).145 Moreover, the 
importance of lipid headgroup charges has been established with Aβ preferentially binding to 
anionic lipid headgroups146–148 more favorably over purely zwitterionic lipids.146–148 The charge 
of the membranes and the peptide to lipid ratio also have profound effects on the secondary 
structure of Aβ.145,149 Previous finding show that under low peptide to lipid ratios Aβ is primarily 
α-helical in nature with high peptide to lipid ratios favoring a β-sheet structure of Aβ.150 Specific 
chemical modifications of a membrane’s extent of unsaturation, conformational changes, 
variation in lipid headgroups, and acyl chains will also have an effect on the hydrophobic and 
electrostatic matching taking place at the protein-lipid interface of membranes.151,152 This is 
noteworthy as the plasma membrane of neurons are highly heterogenous in nature, and changes 
in the composition or charge of lipids can result in differences of fibril elongation rates, 
nucleation times, and aggregate morphology.153,154 
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 Once bound, A can then further migrate and aggregate along the membrane surface.  
Monomeric Aβ exhibits significant lateral mobility, but A becomes increasingly immobile 
following oligomerization.155 This lateral mobility of Aβ has also been related to the properties 
of the surface with highly hydrophilic surfaces inhibiting adhesion of Aβ and highly hydrophobic 
surfaces significantly slowing diffusion rates and inhibiting fibril formation.156 It is hypothesized 
that the regulation of Aβ diffusion to a two-dimensional surface is the primary cause for 
increased rates of fibril formation in the presence of membrane surfaces. In this regard, surface 
density of A on a lipid membrane also plays a role, making the peptide to lipid ratio an 
important parameter to control. Under high peptide to lipid ratios concentrations of Aβ on a 
single vesicle are increased effectively increasing the local concentration of Aβ at the surface and 
prompting accelerated oligomerization of Aβ and fibrillization. Low peptide to lipid ratios exert 
the opposite effect; wherein, the concentration of Aβ at the lipid surface is lower and the time it 
takes for Aβ to diffuse and aggregate significantly increased.149  
 While membrane properties can influence the aggregation of A,153,157,158 features of the 
A peptide also play a role in its interaction with the plasma membrane. For example, the 
aggregation of A40 and A42 on total brain lipid extract bilayers (TBLE) is different.159,160 
Several point mutations with FADs promoted unique aggregate species on TBLE bilayers as 
well.161 This demonstrates that single amino acids within A can play an important role in 
regulating the interaction of A with the plasma membrane. Specifically, lysine in Aβ may be 
responsible for facilitating the electrostatic interactions between the peptide and anionic lipid 
headgroups. Lysine in other protein systems is known to play a role in membrane protein 
anchoring,162 cell-penetrating peptides,163 and antimicrobial peptides.164 These results suggest 
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that the peptide sequence and modification of Aβ are of equal importance in evaluating the 
interactions of Aβ and the membrane.   
1.6 Conclusion 
A aggregation and deposition has long been associated with AD. The aggregation 
process and resulting aggregate species are highly dependent on the chemical properties of 
specific amino acids within A. In addition, the interaction of A with plasma membranes is also 
influenced by specific amino acids. Understanding the of each amino acid in these phenomena 
can provide novel therapeutic targets and strategies.  Here, we explore how targeting specific 
amino acids with A by chemically induced post-translational modifications alters the 
aggregation process, aggregate morphology, and interactions with model lipid membranes. In 
Chapter 2, we examine how increasing the concentration of H2O2, at physiologically relevant 
levels, post translationally modifies Aβ to its sulfoxide derivative Met35[O]. We go on to 
elucidate that oxidation of Aβ alters aggregation, secondary structural transitions, morphologies 
of aggregates, and oligomerization of Aβ in the absence of lipids. In addition, ThT assays are 
performed in the presence of TBLE and polydiacetylene assays (PDA; a lipid binding assay) are 
utilized to clarify the role of an oxidative environment on the Aβ-membrane interactions. Finally, 
we isolated the oxidative effects on Aβ and TBLE to determine the individual roles of oxidation 
on the peptide and membrane and determine the oxidation state of the membrane modulates the 
Aβ-membrane interaction. In Chapter 3, we chemically acetylate Aβ via the addition of sulfo-N-
hydroxysulfosuccinimide acetate (NHSA) with the aim of understanding how the removal of 
lysines cationic charge through acetylation modifies the aggregation of Aβ in the presence and 
absence of TBLE. We observe the inhibition of fibril formation and oligomerization in the 
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absence of lipids with no observations of polymorphic structures. However, ThT assays 
performed in the presence of TBLE restore fibril formation in addition to producing polymorphic 
structures, annular aggregates, at higher acetylation concentrations. Finally, we conclude Chapter 
3 by performing PDA assays to illustrate that acetylation of Aβ reduces membrane binding.    
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for Aβ40 aggregation 
Alzheimer’s disease (AD) is pathologically characterized by the formation of extracellular 
senile plaques, predominately comprised of aggregated β-amyloid (Aβ), deposited in the brain. 
Aβ aggregation can result in a myriad of distinct aggregate species, from soluble oligomers to 
insoluble fibrils. Aβ strongly interacts with membranes, which can be linked to a variety of 
potential toxic mechanism associated with AD. Oxidative damage accompanies the formation of 
Aβ aggregates, with a 10-50% proportion of Aβ aggregates being oxidized in vivo. Hydrogen 
peroxide (H2O2) is a reactive oxygen species implicated in several neurodegenerative diseases. 
Recent evidence has demonstrated that H2O2 concentration fluctuates rapidly in the brain, 
resulting in large concentration spikes, especially in the synaptic cleft. Here, the impact of 
environmental H2O2 on Aβ aggregation in the presence and absence of lipid membranes is 
investigated. Aβ40 was exposed to H2O2, resulting in the selective oxidation of methionine-35 
(Met35) to produce Aβ40Met35[O]. While oxidation mildly reduced the rate of A aggregation 
and produced a distinct fibril morphology at large H2O2 concentrations, H2O2 had a much more 
pronounced impact on A aggregation in the presence of total brain lipid extract vesicles 
(TBLE). The impact of H2O2 on A aggregation in the presence of lipids was associated with a 
reduced affinity of A for the vesicle surface. However, this reduced vesicle affinity was 
predominately associated with lipid peroxidation rather than A oxidation.  
2.1 Introduction: The role of oxidation in Alzheimer’s disease  
 A key pathological feature in Alzheimer’s disease (AD) is the formation of senile plaques 
composed of the amyloid-β peptide (Aβ). Aβ is formed by the successive cleavage of the 
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transmembrane amyloid precursor protein (APP), resulting in varied lengths of Aβ, the most 
common being 40-42 residues long. Aggregation of Aβ results in the formation of insoluble 
plaques, fibrils, protofibrils, and soluble oligomeric intermediates; the latter of which is 
considered to be the dominant neurotoxic species.1–3 Ninety-five percent of AD cases are 
sporadic, with aging being highly associated with developing AD.4  
 A contributing factor in aging is the continuous production of reactive oxygen species 
(ROS)5, which can lead to cellular and molecular damage6,7 and several enzymes function to 
counteract ROS.8 Oxidative modifications of polyunsaturated fatty acids play a role in age-
dependent reduction of membrane fluidity by increasing the rigidity of lipid bilayer membranes 
due to steric hindrance restricting the movement of lipid acyl chains.9,10 Aβ oligomers 
preferentially accumulate near the plasma membrane of oxidatively damaged cells11 and 
enhanced oxidative damage is observed in AD brains.12 The Aβ-induced oxidative stress 
hypothesis states that the principle toxic mechanism underlying AD results from Aβ inducing 
oxidative stress within the brain.13,14 Numerous studies have provided evidence that implicates 
methionine-35 (Met35) in ROS generation, which can be associated with neurotoxicity.15  
 Oxidized variants of Aβ have been detected in mass spectrometry studies of transgenic 
mice,16 Raman spectroscopy of intact senile plaques from AD patients,17 and post-mortem 
analysis of AD patient’s cerebral spinal fluid with 10-50% of Aβ being oxidized.16,18 Aβ 
oxidation occurs at several residues, e.g. histidine and tyrosine, but these require transition 
metals.19 However, Met35 is the only residue susceptible to oxidation directly by hydrogen 
peroxide (H2O2).
20–23 The oxidation of Met35 occurs via a hydroxyl radical addition to the 
thioether of methionine in aqueous media to its sulfoxide derivative.24 The impact of oxidation 
on Aβ aggregation varies greatly in the literature (depending on experimental conditions) as 
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oxidation of Aβ has been observed to increase,25,26 decrease,21,23,27–29 or have no impact on 
aggregation.30–32 In some instances, Aβ oxidation inhibited the formation of intermediate 
aggregates associated with fibril formation. For example, oxidation of Met35 abolished the 
formation of critical nuclei associated with fibril formation,33 and oxidized Aβ40 was limited to 
the formation of dimers.22 Yet other studies have reported the formation of higher ordered fibrils 
from Met35[O] substituted forms of Aβ.21,32,34,35 
 The oxidation state of Aβ influences its toxic properties. Modification of Met35 to its 
sulfoxide derivative, Aβ42-Met35[O], abolished cellular toxicity in 9 to 11-day-old rat 
embryonic hippocampal neuronal cultures.36 Further studies supported the notion that Aβ-
Met35[O] reduced toxicity.32,37,38 Interestingly, Met35Val substitution enhances toxicity, 
illustrating that Met35 is not required for toxicity of Aβ; however, the increased flexibility 
gained by the C-terminus upon this substitution allowed for a higher affinity of Aβ to lipid 
bilayers.39  
 The interaction of Aβ and the plasma membrane has been associated with a variety of 
toxic mechanisms.40–42 Membrane surfaces can (i) modify peptide structure,43 (ii) alter rates of 
amyloid nucleation and growth,44 (iii) promote polymorphic aggregate structures,45,46 and (iv) 
stabilize intermediate aggregate species.47–49 ROS can also cause lipid peroxidation.50 As 
oxidation of Met35 alters the chemical properties of Aβ, the ability of Aβ to bind and insert into 
lipid membranes would be altered with implications for the aggregation process occurring on the 
membrane surface. A potential phenomenon associated with Aβ/lipid interactions under 
oxidative conditions is the localization of Aβ to synapses51 and synaptotoxicity of Aβ oligomers, 
underlying neuronal loss in AD.51,52 Oxidation of Met35 reduces synaptotoxicity and dendrite 
retraction.32 Fast-scan cyclic voltammograms have measured, in real time, H2O2 dynamics in 
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vivo, suggesting that H2O2 fluctuations within the brain and synaptic regions occur ~4-11 times 
per minute,53 creating an opportunity for acute oxidative damage of synaptic Aβ in the presence 
of the plasma membrane. 
 Here, we investigate how oxidative environments, produced by H2O2, influence A40 
aggregation in the presence and absence of model lipid membranes of total brain lipid extract 
(TBLE). TBLE is an excellent model system as it is comprised of a physiologically relevant ratio 
of lipids, i.e. acidic and neutral phospholipids, gangliosides, cholesterol, sphingolipids, and 
isoprenoids. We demonstrate that H2O2 reduces the total fibril load of A40 in the absence of 
lipid until the H2O2 concentration reaches 6.0 mM. At this concentration, a polymorphic fibril 
structure is observed. With the introduction of TBLE vesicles, A40 aggregation is delayed; 
however, the introduction of H2O2 begins to restore A aggregation rates. This correlates with a 
reduced interaction between A40 and the lipid bilayer caused by the presence of H2O2. The 
reduced affinity of A40 for TBLE membranes is more strongly associated with the oxidation of 
lipids rather than the peptide.  
2.2 Materials and Methods  
 2.2.1 Aβ40 Preparation — Synthetic β-Amyloid 1-40 (from AnaSpec Inc., San Jose, CA 
and Alfa Aesar, Tewksbury, MA) was equilibrated to room temperature for 30 min. 
Disaggregation of Aβ40 was achieved by adding 10% NH4OH (w/v) to Aβ40 to obtain a 
concentration of 0.5 mg/mL. After 10 min of incubation and 5 min of bath sonication at room 
temperature, Aβ was aliquoted and snap frozen. Aliquots were lyophilized overnight and stored 
at -80°C. On the day of experiments, Aβ was equilibrated to room temperature and dissolved in a 
60 mM NaOH solution, pH ≥ 11.23. The solution was gently pipette mixed and incubated for 10 
mins at room temperature. Concentrations of the Aβ40 stock solutions, 1.5 mg/mL, was 
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confirmed using a NanoDrop2000 (Thermo Scientific) at an absorbance of 280 nm with an 
extinction coefficient of 1440 M-1 cm-1. A litmus test verified the pH of the reconstituted Aβ to 
be ≥ 11.0. Immediately, Aβ40 was used in experiments or other preparatory methods. 
 2.2.2 Preparation of Oxidized Aβ40 — Oxidized derivatives of Aβ40 were prepared by 
solubilizing lyophilized aliquots with a 60 mM NaOH solution and diluted to a final 
concentration of 20 μM in a 20 mM HEPES 150 mM NaCl buffer (pH = 7.23) containing 3% 
(w/v) H2O2, 980 mM. Samples were incubated for 3 h before being dialyzed against 18 MΩ 
water overnight in a Slide-A-Lyzer MINI Dialysis Device (Thermo Scientific, Waltham, MA) 
with a 3.5 kDa molecular weight cut off. Samples were alkalified for extraction by the addition 
of a 10% NH4OH (w/v) solution. Extracts were lyophilized, re-disaggregated, and lyophilized 
again before storage at -80°C.  
 2.2.3 Liquid Chromatography Mass Spectrometry (LC-MS) — Lyophilized aliquots of 
Aβ40 were removed from -80°C and allowed to reach RT over the course of 30 min before being 
solublized in 60 mM NaOH (pH ≥11.23) and incubated for 10 min at RT without agitation. 
Finally, the stock Aβ40•NaOH solution was bath sonicated for 5 min. Aβ40 (20μM) was incubated 
at 37°C in a HEPES buffering solution (20mM HEPES, 150mM NaCl pH = 7.23) with varying 
amounts of H2O2 (0, 0.1, 1.0, 3.0, 6.0 mM). Solutions were aliquoted for each oxidation 
condition and incubated without agitation. At specific time points (0, 15, 30, 45, 60, 120, 180, 
240, and 300 min) aliquots of each oxidation condition were snap frozen and lyophilized 
overnight to remove H2O2. The following day, samples were diluted in 1% formic acid/water 
(v/v) right before being introduced to the LC-MS.  
 Chromatography was performed on a C18 column (ZORBAX RRHD Eclipse XDB 80Å 
C18, 2.1 x 100 mm, 1.8 µm; Agilent, Santa Clara, CA) utilizing a mobile phase of 0.1% 
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formic/water (v/v) (%A) and 0.1% formic acid/acetonitrile (v/v) (%B) with a gradient of 5%B to 
60%B over 4.5 min with a flowrate of 300 μL/min. A Q Exactive (Thermo Scientific) mass 
spectrometer was operated in positive ion mode and scanned over a mass-to-charge (m/z) range 
of 500-2000 at a 70,000 resolution.  
 2.2.4 Mass Spectrometry Analysis — Percent oxidation was calculated by determining the 
area (total ion chromatogram, TIC) of the oxidized peak, retention time of ~5.5-5.7 min, and 
unoxidized peak, retention time of ~5.9-6.0 min, and dividing by the summation of the total peak 
area. Peak areas encompassed all charge states from m/z 500-2000. Unoxidized and oxidized 
Aβ40 ions were clearly resolved in the TIC as observed in the different mass spectra. However, 
the oxidized peak did contain minor contributions from the doubly oxidized sulfone peptide, but 
its contribution was consistently less than 1% and was considered negligible. 
 2.2.5 Sample preparation for 1H NMR and analysis of measurements — 1H NMR 
experiments were run on an INOVAUnity 600 MHz spectrometer (proton frequency, 599.67 MHz) 
equipped with a triple-resonance z-axis pulsed field gradient 5 mm probe. Aβ40 samples where 
oxidized, as mentioned above, for 3 h or 24 h at ambient temperature without agitation. 
Lyophilized aliquots of Aβ40 or oxidized Aβ40 were solubilized in 60 mM NaOD in D2O and 
diluted to 10 μM with a 100 mM Na3PO4 deuterated buffer. Then a 700 µL solution was placed 
in 5 mm NMR tube and the 1H NMR spectra with a PRESAT sequence were acquired for 30 min 
to 1 h. The FIDs of the 1H NMR spectra were processed using the commercially available NMR 
software package ACD/Spectrus Processor 2017.2 (Advanced Chemistry Development, Inc; 
http://, File Version S70S41, Build 98721, 19 Dec 2017). 1H NMR chemical shifts were 
referenced to a residual proton peak (HDO) of water at 4.63 ppm, and the FID’s of 1H NMR 
were processed with a line broadening function of 2 Hz. 
2. Hydrogen peroxide modifies Aβ-membrane interactions   
with implications for Aβ40 aggregation  41 
 2.2.6 Thioflavin-T Fluorescence Assay (ThT) — Lyophilized aliquots of Aβ40 were 
removed from -80°C storage and allowed to reach RT over the course of 30 min. Aβ40 was 
solubilized with 60 mM NaOH (pH ≥11.23), incubated, and sonicated for 5 min before being 
diluted into a HEPES buffer (20 mM HEPES, 150 mM NaCl pH = 7.23) at 20 μM Aβ40, as 
previously mentioned. The formation of higher ordered β-sheet aggregates was monitored via a 
thioflavin-T (ThT; Sigma Aldrich, St. Louis, MO) assay. In a 96-well plate Aβ40 was aggregated 
in a HEPES buffering (20 mM HEPES 150 mM NaCl pH = 7.23) solution containing ThT at a 
1.5 molar ratio to Aβ40, with varying final concentrations of H2O2 (0, 0.1, 1.0, 3.0, 6.0 mM) 
relative to Aβ’s final concentration. Additionally, to facilitate homogenous mixing across the 96-
well plate and enhance the reproducibility of aggregation kinetics 3 mm borosilicate beads were 
added to each well. Well plates were sealed and reactions were performed at 37°C. Fluorescence 
intensities were measured at excitation and emission wavelengths of 440 nm and 484 nm, 
respectively, utilizing a SpectraMax M5 or M2 Multi-Mode plate reader (Molecular Devices, 
Sunnyvale, CA) to measure in 5 min interval readings with 10 s shaking between intervals. 
Assays preformed in the presence of TBLE were carried out using the same procedure (see Lipid 
Vesicle Preparation). The ThT signal in the presence of TBLE exhibited only a slight increase in 
fluorescence in the background signal which was constant across all variables and subtracted out 
during baseline correction. 
 Data analysis was performed employing GraphPad Prism 6 to average across triplicates, 
baseline correct, and perform error analysis reported as a standard error mean (SEM). Kinetic 
parameters of aggregation such as nucleation lag-phase time (tlag) were obtained empirically by 
fitting the ThT traces for each experiment to a Boltzmann sigmodal function, Equation 1.54,55  
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𝑌 = (𝑦𝑖 +𝑚𝑖𝑥) +
𝑦𝑓+𝑚𝑓𝑥
1+𝑒
−(
𝑥−𝑥𝑜
𝜏 )
        (1) 
Utilizing GraphPad Prism 6 the initial lag-phase and plateau regions of the curves are defined by 
linear fits where the initial fluorescence and slope are defined by, yi and mi, and the final 
fluorescence and slope as, yf and mf, respectively. The time to reach the half maximum of the 
curve is defined by xo and the elongation time constant of the growth phase is defined as τ. As a 
nonideal sigmodal function, no constraints were applied. A least squares fitting operation was 
then performed for a maximum iteration limit of 1000. The lag-phase time was calculated from 
the kinetic parameters, tlag=xo-2τ. The slope of the growth phase is associated with the growth of 
fibrils. The slope was calculated by normalizing the ThT traces to the mean maximum response 
of control group (no H2O2 added) within each independent experiment for comparison across 
experiments. To obtain the relative slope of the growth phase, Rslope(h
-1) the linear fits of the 
growth phase were performed by defining the boundaries of the fit to only include the linear 
region between the lag-phase and the plateau region as visually determined for each ThT curve. 
The maximum signal of fluorescence at steady state was calculate using a linear fit over the 
plateau region of the sigmodal curve. This was accomplished by adjusting the starting point of 
the data to be fit and moving it further back to optimize the r2 value.  Initial starting point points 
were visually determined to be near the inflection point where the sigmoidal curve enters the 
plateau region. The fits were performed from these starting points to the end of the data set. Once 
the boundaries were defined, the average fluorescence signal within this plateau region was 
determined. For comparison between trials, these were converted to the relative fluorescence at 
steady state (RFss) by dividing each value by the control experiment (no H2O2 for that 
experiment). All kinetic parameters were then averaged from triplicates of independent 
experiments to determine the mean ± SEM. Significance was reported as greater than 95% 
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confidence calculated using a standard Student’s T-test to determine variations in parameters 
across varied H2O2 concentrations. 
2.2.7 Atomic force microscopy — Aβ40 was prepared in the same manner as the ThT 
assays. Samples were incubated using a Spectra Max M5 plater reader’s shaker and incubator, 
37°C, to maintain the same experimental conditions as used in the ThT assays. At 1 h intervals. 2 
μL samples were taken and deposited on freshly cleaved mica. Samples were allowed to incubate 
for 1 min before being washed with 200 μL of 18 MΩ water and dried immediately with 
compressed air. Imaging of samples was performed on a Nanoscope V Multimode Atomic Force 
Microscope (AFM) (Veeco, Santa Barbara, CA) with a closed-loop vertical engage J-scanner. 
All images were obtained in tapping mode under ex-situ conditions utilizing a diving-board-
shaped silicon oxide cantilever with a spring constant of 40 N/m and the resonance frequency of 
~300 kHz. 
 AFM image processing and analysis was performed in Matlab (MathWorks, Natick, MA) 
by utilizing the imaging processing toolbox.56 A 3rd order polynomial flattening algorithm was 
used to correct for background curvature. Binary maps were created by using an established 
height threshold (z = 0.99 nm), and discrete aggregates were selected by implementing 
recognition algorithms to the binary maps. Physical features of individual aggregates (e.g., 
height, volume, diameter, shape factor, length, aspect ratio, length, and area covered) were 
measured. A minimum of five 5 × 5 µm AFM images for each time point was analyzed, resulting 
in a minimum of 125 µm2 of surface area analyzed. 
The number of oligomeric aggregates per unit area was determined through a filtering 
algorithm. Thresholds for filtering oligomeric aggregates were defined as heights between 1.0 
and 10 nm with an aspect ratio between 1.0-2.5. Fibril aggregates per unit area were counted 
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individually by hand and divided by total area of the image.56,57 The percent of the mica surface 
covered by fibrils was determined by filtering out non-fibrillar aggregates (based on aspect ratio) 
from the above mentioned binary map. The remaining number of pixels in the binary map 
associated with fibril aggregates were summed and divided by the total number of pixels in the 
AFM image. Populations of oligomers and fibrils, along with the percent area covered by fibrils, 
were plotted using GraphPad Prism 6 to average across replicates and perform error analysis 
reported as a standard error mean (SEM). 
 2.2.8 Circular Dichroism Spectroscopy — Samples containing 20 μM Aβ40 and different 
concentrations of H2O2 (0, 1.0, 6.0 mM) in a 10 mM K2HPO4 50 mM Na2SO4 (pH = 7.23) 
buffer, were prepared in a 96-well plate and incubated on a Spectra Max M5 plate reader, as 
described previously here. Samples were taken in 1 h intervals and transferred to a 1-mm quartz 
cell. A Jasco-810 spectropolarimeter (Japan Spectroscopic Company, Tokyo, Japan) was used to 
record spectra from 190-260 nm at 0.5 nm resolution at ambient temperature. An average of five 
spectra were collected, averaged, and repeated three more times over the course of 1 h to ensure 
that any continued aggregation had not significantly changed spectra between the initial and final 
reading. Deconvolution of spectra was performed using BeStSel (http://bestsel.elte.hu/)58,59 and 
plotted using GraphPad Prism 6. Experiments were performed alongside their equivalent ThT 
assay experiment to ensure the accuracy of aggregation kinetics. 
 2.2.9 Lipid Vesicle Preparation — Lyophilized total brain lipid extracts (TBLE; Avanti 
Polar Lipids, Alabaster, AL) were dissolved in chloroform at 25 mg/mL, aliquoted into 5 mg 
amounts, dried in vacuo producing a transparent film, and stored at -20°C. Oxidation of TBLE 
samples was performed by hydrating the lipid film with a 3% (w/v) H2O2 solution and incubating 
at 60°C and 1400 rpm for 3 h on an Eppendorf Thermomixer. Unoxidized and oxidized TBLE 
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samples were hydrated with a HEPES buffer (20 mM HEPES 150 mM NaCl buffer pH = 7.23) 
and incubated for 30 min at 60°C and 1400 rpm in a Thermomixer. Lipid samples were subjected 
to 7 freeze-thaw cycles followed by 30 mins of bath sonication. Lipid stocks were heated and 
kept at 60°C during extrusion through 100 nm polycarbonate membrane filter. Extruded lipids 
were kept at 37°C before being added to a 96-well plate for a final concentration of 0.432 
mg/mL. To determine the extent of lipid peroxidation for pre-oxidized lipid experiments, a Lipid 
Hydroperoxide (LPO) Assay Kit (Abnova) was used.  
 2.2.10 Preparation of TBLE/Polydiacetylene Vesicles (PDA) — Five-milligram aliquots 
of TBLE or TBLEOx were dissolved in a 1:1 chloroform: ethanol solution. Separately 8.4 mg of 
10,12-tricosadiynoic acid (GFS Chemicals, Columbus, OH) was also dissolved in a 1:1 
chloroform: ethanol solution. The two were combined in a glass vial at a 60:40 mass ratio of 
PDA to TBLE and solvent was removed in vacuo to produce a TBLE/PDA film. Eight milliliters 
of a HEPES buffer (20 mM HEPES 150 mM NaCl buffer pH = 7.23) was heated to 75°C and 
used to hydrate the TBLE/PDA film. The solution was probe sonicated for 10 mins at 180 W 
then stored at 4°C, protected from light, overnight. The following day the TBLE/PDA or 
TBLEOx/PDA vesicles are transferred to a 100-mL beaker and stirred under a black box while 
being irradiated at 254 nm for 10 mins through the utilization of a TLC lamp. Experiments were 
conducted in a Costar 96 black clear flat bottom well plate with the addition of 3 mm borosilicate 
glass beads. Utilizing a SpectraMax M2 or M5 Multi-Mode plate reader (Molecular Devices, 
Sunnyvale, CA), the rates of peptide-lipid interactions were observed fluorescently under 
ambient temperature and at excitation and emission wavelengths of 485 nm and 560 nm, 
respectively. Data analysis was performed using the software suite GraphPad Prism 6. Briefly, 
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mean triplicates were baseline corrected with the matching vehicle controls and adjusted relative 
to the minimum and maximum experimental variable. 
2.3 Results  
 2.3.1 Oxidation of Aβ40 via H2O2 is selective for methionine-35. To determine the extent 
and selectivity of Aβ40 oxidation in the presence of H2O2, 20 µM solutions of Aβ40 were exposed 
to H2O2 at concentrations ranging from 0.1 mM to 6.0 mM. The resulting solutions were 
incubated at room temperature without agitation. Aliquots were taken at various time points 
ranging from 0 min to 300 min and accurate protein masses were determined from charge state 
envolopes within high-resolution MS spectra (Figure. 2.1).  
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Figure 2.1. H2O2 oxidation of Aβ40 is selective for methionine-35. (A) Mass spectrum from 
600-1200 m/z illustrating that the +4, +5, +6 m/z charge states exhibit a 16 Da mass shift when 
unoxidized Aβ40, Met (green), is exposed to H2O2 producing a singly-oxidized Aβ40 variant, 
MetOx (red). (B) Percent oxidation of Aβ40 as determined from the oxidized peak area (TIC) of 
Aβ40 relative to the total Aβ40 peak area. Aβ40 was incubation under varied H2O2 concentrations 
0.0 mM (green), 0.1 mM (blue), 1.0 mM (purple), 3.0 mM (orange), 6.0 mM (red), and varied 
lengths of time indicated by symbols (see key). Lines represent the mean ± SEM percent 
oxidation over the time course of the experiments. (C) The 1H NMR spectrum of Aβ40 dissolved in 
60 mM NaOD and diluted to 10 μM in 100 mM Na3PO4 deuterated buffer at pH 7.23. Total 
acquisition time was over 30-60 min. The 1H NMR spectrum was referenced to the residual 
proton peak of HDO at 4.63 ppm. In the 1H NMR spectrum of unoxidized Aβ40 (black) the singlet 
peak 1.99 ppm belongs to εCH3 of Met. Oxidation of Aβ40 was achieved by addition of 3% H2O2 
(w/v) for 3 h and 24 h before its removal via lyophilization. The 1H NMR spectra (blue and red) 
exhibited downfield shits indicated by arrows at 2.55 ppm and 2.95 ppm which were assigned to 
εCH3 of Met-sulfoxide and Met-sulfone, respectively.  
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 The mass spectra showed a single oxidation event consistent with the oxidation of Met35 
to a sulfoxide derivative under all conditions from the analysis of the +4, +5, and +6 charge state 
ions. Oxidation of Aβ40 with H2O2 concentrations up to 6.0 mM predominatley resulted in the 
sulfoxide rather than the sulfone. By comparing the spectral peaks for the unoxidized states (+4 
ion at m/z 1083, +5 ion at m/z 866.8, +6 ion at m/z 722.5) to the respective oxidized peaks (+4 
ion at m/z 1087, +5 ion at m/z 870.0, +6 ion at m/z 725.2), the extent of oxidation at different 
H2O2 concentrations was determined as a function of time. Without the addition of H2O2, a small 
amount of oxidized Aβ40 was present (6.3% on average over all time points with 18% of Aβ 
being oxidized by 5 h of incubation), which is inherent to the peptide preparation and 
disaggregation procedure (Figure. 2.1B). The addition of H2O2 at 5:1 molar ratio (0.1 mM H2O2) 
did not significantly increase the extent of Met35 oxidation (6.8% on average over all time points 
with 17% of Aβ being oxidized by 5 h of incubation). At 50:1 molar ratio of H2O2 (1.0 mM 
H2O2) a significant increase in Met35 oxidation is observed (14% on average over all time points 
with 36% of Aβ being oxidized by 5 h of incubation). Additional increases in H2O2 (150:1 and 
300:1) yielded increases in Met35 oxidation (24% and 36% on average over all time points with 
50% and 67% of Aβ being oxidized by 5 h of incubation, respectively). The observed selective 
oxidation of Met35 by treatment with H2O2 is consistent with previous reports,
20–23 but it was 
essential to establish reliable reaction parameters for further experimentation. Note, the oxidation 
of other residues within Aβ has been observed; however, these oxidation events require transition 
state metals.19,21  
 To verify the selectivity of oxidation at Met35 under experimental conditions, 20 µM 
samples of Aβ40 were incubated with an excess of H2O2 (980 mM) for 3 h and 24 h. After a 
disaggregation step, these Aβ40 samples were analyzed by 1H NMR spectroscopy (Figure. 2.1C). 
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The 1H NMR spectrum of unoxidized Aβ40 shows a singlet peak at 1.99 ppm which belongs to 
εCH3 of Met. The 1H NMR spectra reveal two relatively downfield singlet peaks at 2.55 ppm and 
2.95 ppm, respectively and were assigned directly to the oxidized species of Met35 (Met-
sulfoxide and Met-sulfone). Oxidation of other residues was not observed at these harsher 
conditions. 
 2.3.2 Methionine oxidation decreases total fibril content associated with Aβ40 
aggregation. To establish if the presence of H2O2 would alter the aggregation process of Aβ40, 
the rate of fibril formation was monitored with a ThT assay, which detects β-sheet formation 
associated with fibrils (Figure 2.2A). Amyloid formation occurs via a characteristic two-step 
process consisting of a lag phase and growth phase. The lag phase is associated with the slow 
formation of a critical nucleus that triggers fibrillization. The growth phase is associated with 
fibril elongation. For all concentrations of H2O2, the lag-phase of Aβ40 aggregation was similar 
(Figure. 2.2B). The relative slope of the growth phase, Rslope (h
-1), were similar at lower H2O2 
concentrations, but interestingly, the increase of oxidation conditions to that of 3.0 mM and 6.0 
mM H2O2 significantly reduced slopes of the growth phase, from 0.62 ± 0.041 h
-1 and 0.24 ± 
0.018 h-1 respectively, when compared to the control 0.85 ± 0.032 h-1 (Figure 2.2C). However, 
once steady state was achieved (see Figure 2.3 for all individual ThT curves), the magnitude of 
total fibril content (as measured by the relative fluorescence at steady state) was reduced as the 
amount of H2O2 present was increased with a statistical significance starting at 1.0 mM H2O2 
compared to control (Figure 2.2D).  
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Figure 2.2. Impact of H2O2 on A40 
aggregation (A) Average ThT assays of 20 
µM Aβ40 (green) aggregation performed at 
37 °C with the addition of 0.1 mM (blue), 1.0 
mM (purple), 3.0 mM (orange), and 6.0 mM 
H2O2 (red). Continuous lines represent non-
linear best fits (Equation 1) to the average 
experimental traces. The lag-phase was 
calculated from non-linear fits of three 
independent experiments represented by 
bar-graphs as the mean ± SEM. Kinetic 
parameters include the (B) lag-phase, tlag, 
(C) relative slope of the normalized ThT 
curves, Rslope (h-1), and (D) normalized 
steady-state maximum fluorescent response, 
and relative fluorescence at steady state. P-
values are indicated as follows (*) P ≤ 0.05, 
(**) P ≤ 0.01, (***) P ≤ 0.001, and (****) P 
≤ 0.0001. 
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Figure 2.3. Individual curves for ThT assays. Assays performed at a concentration of 20 µM 
Aβ40 (green) aggregation performed at 37 °C in the absence of H2O2 (green) or with the addition 
of 0.1 mM (blue), 1.0 mM (purple), 3.0 mM (orange), and 6.0 mM H2O2 (red). Three independent 
plates were run. 
 
 2.3.3 Increased oxidation modifies the distribution of Aβ40 aggregate species. It is well-
known that variations in the chemical environment can induce polymorphic aggregates in Aβ,60–
64 that is, fibrils of unique morphology and structure. To determine if oxidation could result in 
polymorphic Aβ aggregates, incubations of Aβ with various concentrations of H2O2 were 
sampled every hour for analysis by atomic force microscopy (AFM) to determine the impact of 
oxidative environments on aggregate species and morphology (Figure 2.4). To determine 
populations of different aggregate species, oligomers were defined as particles larger than 1 nm 
in height with an aspect ratio (defined as long axis/short axis) of less than 2.5, indicating a 
globular morphology. Due to the high density of crossing fibrils in some images, the number of 
fibrils were manually counted. To prevent bias due to overcounting, individual fibrils were 
marked by tracing along the contour of each fibril in Photoshop. As fibril length can vary greatly, 
the total fibril load at any given time point was also determined by percent area of the mica 
surface covered by fibril aggregates (Figure 2.4B). At time point 0 h, no observable oligomer or 
fibrils were observed for every condition (H2O2 concentration). Within the first-hour, the number 
of oligomeric aggregates grew similarly for all conditions to higher than ~20 oligomers per µm2; 
however, these oligomer populations dramatically dropped after 2 h (a 2 to 4-fold reduction). 
This decrease in oligomers under each condition coincided with the appearance of fibrils. The 
appearance of fibril after 2 h is consistent with the lag phases determined from the ThT assays 
(Figure 2.2A). The number of oligomers continued to decrease as the fibril load increased for 
each condition. With that being stated, the decrease in oligomers (and subsequent increase in 
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fibrils) for the 6.0 mM H2O2 condition was significantly less pronounced compared with the 
other conditions, with a noticeable oligomer population still observed into the 3rd h of incubation. 
The number of fibrils observed at any given time point as a function of H2O2 concentration was 
consistent with the total fibril load associated with the ThT assays, that is, the number of fibrils 
and the surface area covered by fibrils decreases as the concentration of H2O2 increases. 
 
Figure 2.4. Atomic force microscopy analysis of A40 aggregation as a function of H2O2 
concentration. (A) Representative AFM images of 20 µM Aβ40 incubated at 37 °C with the 
addition of 0.1 mM, 1.0 mM, 3.0 mM, and 6.0 mM H2O2 taken at several time points. The color 
scale is the same for each image. (B) Determination of the number of oligomers and fibrils per 
unit area and the percent area of the mica surface covered by fibrils as observed in AFM images 
as a function of time. (C) Height histograms of oligomers observed in AFM images. 
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 Under all conditions, the distribution of oligomer size was consistent with a mode of 
oligomer size of 2.8-3.2 nm in height (Figure 2.4C). In contrast, there was a distinct polymorphic 
fibril structure formed in the presence of 6.0 mM H2O2 (Figure 2.5). With no H2O2 and H2O2 
concentrations up to 3.0 mM, the average height along the contour of the fibril was ~3 nm. At 
these conditions, there were often regions where fibrils were bundled or crisscrossed, and these 
regions were thicker. When H2O2 concentration was 6.0 mM, the height along the contour of the 
fibrils was only ~2 nm, suggesting that the fibrils formed under this condition were structurally 
different. Interestingly, this is also the condition for which the elongation rate was significantly 
different and that the amount of Met35 oxidation can reach 50% within 2 hours of incubation. 
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Figure 2.5. Comparison of A40 fibrils 
formed in the presence of varying 
concentrations of H2O2. (A) AFM images of 
fibrils formed by A40 in the presence of 
H2O2 concentrations ranging from 0-6.0 
mM. The color scale is the same for each 
image. The black lines in each image 
corresponds to the height profile to the right 
of the image. In the height profile, a red 
dashed line is provided at a height of 3 nm 
for visual reference. (B) Histograms of the 
average height along the contour of fibrils 
observed in AFM images. 
 
 2.3.4 Secondary structural transitions of Aβ40 are altered by H2O2. To determine if 
oxidative environments altered secondary structural changes in Aβ40 associated with aggregation, 
circular dichroism (CD) spectra were collected of Aβ40 exposed to various concentrations of 
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H2O2 as a function of time (Figure 2.6). In the absence of H2O2, Aβ40 underwent a clear 
structural transition between 2 and 3 h of incubation. Specifically, during the first 2 h of 
incubation, Aβ40 was predominately random coil. At 3 h, there was a significant increase in α-
helical content, suggesting the appearance of an α-helical intermediate that has been 
proposed.29,65–67 After 3 h, the parallel β-sheet content of Aβ40 increased, consistent with 
extensive fibril formation.  
 
Figure 2.6. Secondary Structural Transitions Altered by H2O2. Time-dependent changes in 
CD spectra recorded from 190-260 nm over 5 h, discontinuously, at 25°C from 20μM Aβ40 
samples incubated continuously at 37 °C in a 10 mM K2HPO4 50 mM Na2SO4 buffer (pH 7.23) 
containing (A) 0.0 mM H2O2, (B) 1.0 mM H2O2, and (C) 6.0 mM H2O2. Changes in secondary 
structure as a function of time from CD deconvolution presented as percent contribution of 
helical content (red), antiparallel β-sheet (blue), parallel β-sheet (purple), and turn/random coil 
regions (green) for Aβ40 in the presence of (D) 0.0 mM H2O2, (E) 1.0 mM H2O2, and (F) 6.0 mM 
H2O2. Each spectra was deconvoluted using the online program BeStSel (Beta Structure 
Selection, http://bestsel.elte.hu/). 
 
 Adding H2O2 to the Aβ40 incubations at concentration of 1.0 mM and 6.0 mM altered the 
development of secondary structural elements as a function of time. Neither condition caused a 
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significant change in secondary structure of Aβ40 for the first 2 h of incubation, that is, random 
coil was the dominant structural element. At 3 h, the rise of α-helical structure in Aβ40 was still 
apparent with 1.0 mM H2O2. The transition from the α-helical intermediate to β-sheet structure 
associated with fibrillization still occurred in the presence of 1.0 mM H2O2 after 3 h of 
incubation, but this α-helical content persisted at the 4 and 5 h time points. Similar to 
aggregation in the absence of H2O2, there was an increase in parallel β-sheet content. At the 6.0 
mM concentration of H2O2, the transition away from random coil structure was not apparent over 
the time course of the experiment, which is consistent with previously published results for Aβ42 
and Aβ42-Met35[O]20 and further supports the notion that fibrils observed under this condition 
represent a polymorph when compared to Aβ fibrils formed in the absence of H2O2.  
 2.3.5 The presence of TBLE LUVs impedes aggregation of Aβ40. To understand how the 
presence of lipid membranes alter Aβ40 aggregation, and how oxidation may modulate that 
interaction, we evaluated Aβ40 aggregation in the presence of large unilamellar vesicles (LUV) of 
TBLE with ThT assays. Due to inconsistent results in the literature demonstrating the 
increase68,69 or decreases70,71 of lag-phase behavior for Aβ aggregation in the presence of lipids, 
first performed to understand how Aβ aggregates as a function of lipid mass for the specific lipid 
system and Aβ preparation protocols used here (Figure 2.7). These experiments were performed 
in the absence of H2O2 and at an Aβ40 concentration of 20 µM. As the lipid to peptide ratio was 
increased, the lag phase associated with Aβ40 aggregation (in the absence of H2O2) extended, 
increasing by ~3.5 h when the lipid to peptide ratio exceeded 50:1 (Figure 2.7B). These extended 
lag phases are attributable to the effect of interactions between Aβ40 and the LUVs. The slope of 
the growth phase and extent of β-sheet formation at steady state varied extensively without a 
clear trend in the presence of TBLE.  
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Figure 2.7. Presence of TBLE extends 
lag-phase of Aβ40 aggregation (A) 
Average ThT assays of 20 µM Aβ40 
performed at 37°C in the absence (green) 
and presence of TBLE vesicles various 
lipid-to-peptide (L:P) ratios; 10:1 (blue), 
20:1 (purple), 30:1 (orange), 50:1 (red), 
and 110:1 (pink). Equation 1 was utilized 
to provide a non-linear best fit to the 
average of triplicate traces represented as 
continuous lines. (B) The lag-phase, tlag, 
was calculated from non-linear fits of 
experiments represented by bar-graphs as 
the mean ± SEM. (C) The relative slope of 
the normalized ThT curves, Rslope (h-1), and 
(D) relative fluorescence at steady state, 
RFss, were calculated of the linear fits of 
the growth phase and plateau region of 
the ThT curves, respectively. 
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 Having established how TBLE alters Aβ40 aggregation in the absence of H2O2, a series of 
ThT assays were run with increasing amounts of H2O2 (from 0.1 mM to 6.0 mM) and a lipid to 
peptide ratio of 30:1 (Figure 2.8). At the 30:1 lipid to peptide ratio, the lag phase was 3.61 ± 0.39 
h in the absence of H2O2. Increasing H2O2 concentration systematically reduced the lag phase 
associated with Aβ aggregation. The effect was significant enough that at the highest 
concentration of H2O2, 6.0 mM, the lag-phase was roughly equivalent to the lag-phases of Aβ40 
observed in Figure 2.2 in which no lipid was present (1.10 ± 0.51 h and 1.27 ± 0.06 h, 
respectively), suggesting that increased H2O2 concentration decreases the interaction between 
Aβ40 and lipids. Once nucleation occurred, the slope of the growth phase, associated with fibril 
elongation, remained unchanged as H2O2 concentration was increased up to a concentration of 
3.0 mM. At 6.0 mM H2O2 the slope of the growth phase abruptly dropped to 0.21 ± 0.015 h
-1. 
The magnitude of ThT signal once steady state Aβ aggregation was reached also diminished with 
increased exposure to H2O2. Collectively, these observations suggest that the oxidative 
environment provided by H2O2 reduced the affinity of Aβ for the lipid bilayer surface, causing 
the characteristics of Aβ aggregation to shift toward those associated with the absence of lipids. 
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Figure 2.8. Impact of H2O2 on A40 
aggregation in the presence of TBLE 
vesicles (A) Average ThT assays of 20 µM 
Aβ40 (green) aggregation in the presence of 
TBLE vesicles (30:1 lipid to peptide ratio) 
performed at 37 °C with the addition of 0.1 
mM (blue), 1.0 mM (purple), 3.0 mM 
(orange), and 6.0 mM H2O2 (red). 
Continuous lines represent non-linear best 
fits (Equation 1) to the average experimental 
traces. The lag-phase was calculated from 
non-linear fits of three independent 
experiments represented by bar-graphs as 
the mean ± SEM. Kinetic parameters include 
the (B) lag-phase, tlag, (C) relative slope of 
the normalized ThT curves, Rslope (h-1), and 
(D) normalized steady-state maximum 
fluorescent response, and relative 
fluorescence at steady state. P-values are 
indicated as follows (*) P ≤ 0.05, (**) P ≤ 
0.01, (***) P ≤ 0.001, and (****) P ≤ 
0.0001. 
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 2.3.6 Oxidation reduces Aβ/lipid interaction and lipid oxidation plays a large role. As the 
ThT assays suggested a reduced interaction between the lipid vesicles and Aβ40, a 
polydiacetylene (PDA) lipid binding assay was performed to measure the total interaction 
between Aβ40 and lipid membranes (Figure 2.9A). Polydiacetylene is a lipid moiety that can be 
incorporated into vesicles and photo-crosslinked to create vesicles that are sensitive to 
mechanical perturbations associated with peptide binding and aggregation, resulting in both a 
color change (blue to red) and enhanced fluorescence. Here, the PDA was incorporated into 
TBLE vesicles, and the response upon exposure to Aβ40 was measured fluorescently. Controls 
were performed demonstrating that exposure to various concentration of H2O2 did not invoke a 
fluorescent response in the PDA assay in the absence of Aβ and used for background correction. 
Upon exposure of TBLE/PDA vesicles to Aβ40, the fluorescent signal steadily increases as the 
peptide binds and aggregates on vesicles. While the presence of 0.1 mM and 1.0 mM H2O2 did 
not significantly alter the interaction between Aβ40 and the vesicles, H2O2 concentrations of 3.0 
mM and higher resulted in a significant decrease in peptide/lipid interaction, which correlates 
with the ThT data presented in Figure 2.8. 
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Figure 2.9. Aβ40 binding assays performed 
with TBLE/PDA vesicles. (A) PDA 
fluorescence response (λEx 485 nm, λEm 560 
nm) as a function of time when exposed to 20 
µM Aβ40 (green) incubated at 25°C and in 
the presence of 0.1 mM (blue), 1.0 mM 
(purple), 3.0 mM (orange), and 6.0 mM 
H2O2 (red). (B) Isolated effects of varied 
oxidation states of TBLE and Aβ40 on 
peptide-membrane interactions measured by 
PDA fluorescence incubated at 25°C. PDA 
assays were performed with the following 
combinations; unoxidized TBLE/PDA and 
Aβ40 (green, circle), TBLE/PDA and Aβ40 
oxidized (orange, triangle), TBLEOx/PDA 
and Aβ40 (purple, diamond), lastly 
TBLEOx/PDA and Aβ40 oxidized (red, 
square). 
 
 
 H2O2 can oxidize not only Aβ but also lipids. To elucidate if oxidation of Aβ40, TBLE 
LUVs, or both was the modulator of the observed decreased peptide/lipid interaction, additional 
lipid binding assays were performed in which the oxidation of the varying components was 
controlled. Briefly, Aβ40 and TBLE were oxidized separately and lyophilized to remove residual 
H2O2. These pre-oxidized materials were then used for a series of TBLE/PDA assays. The pre-
oxidized stock of Aβ40 was 76% oxidized (as measured by MS), and the pre-oxidized stock of 
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TBLE was 62% oxidized (as determined by an LPO Assay Kit). The oxidized form of TBLE was 
used in conjunction with PDA to create an oxidized-TBLE/PDA vesicles (TBLEOx). Due to 
concerns about changes in solubility upon oxidation of the lipids, it was necessary that the total 
lipid mass delivered to each sample be standardized. Standardization was carried out through the 
use of optical density measurements at 470 nm conducted before photoactivation of TBLE/PDA 
vesicles. Maximum responses of positive controls were also compared and used to standardize 
the responses across different TBLE/PDA batches; maximum fluorescent intensities were found 
to be directly comparable even before normalizing across batches. 
 When both oxidized TBLE (TBLEOX) and Aβ40 (Aβ40Ox) were used in the PDA assay, a 
significant decrease in peptide/lipid interaction was observed compared with using un-oxidized 
TBLE and Aβ40, which is consistent with the PDA assay results from Figure 2.9B. However, 
when only Aβ40 was oxidized, the interaction of the peptide with un-oxidized TBLE vesicles 
increased in comparison with un-oxidized Aβ40 (Figure 2.9B), which is the opposite effect that 
was observed when H2O2 was just added directly to the interaction. When TBLEOx was used in 
the PDA assay, exposure to un-oxidized Aβ40 resulted in an even greater decrease in the 
measured peptide/lipid interaction compared with oxidized Aβ40. These observations suggest that 
oxidation of Aβ and lipid both play a role in their co-interaction, but with opposite effects. That 
is, oxidation of Aβ enhances the affinity for TBLE based membranes, while lipid oxidation 
inhibits the binding of Aβ to membranes. Of the two, lipid oxidation appears to have a larger 
impact on the peptide/lipid interaction.  
  
2. Hydrogen peroxide modifies Aβ-membrane interactions   
with implications for Aβ40 aggregation  64 
2.4 Discussion 
 A number of studies have investigated the impact of Met35 oxidation on A aggregation 
in the absence of lipids with varying results. Some studies suggest that Met35 oxidation 
enhances aggregation to fibrils;26 meanwhile, others suggest it impedes aggregation.23,25,72 A 
complicating factor in evaluating studies of A aggregation and structure is divergent 
preparatory conditions greatly influence experimental outcomes.73 Of these reports, the study by 
Gu and Viles is most directly comparable to our results, as the same A preparation protocol was 
used, oxidation was performed with a similar range of H2O2, and the aggregation occurs with 
mixtures of oxidized and unoxidized A.23 In fact, the extent of oxidation in their study and ours 
under similar concentrations of H2O2 were comparable. While Gu and Viles observed a H2O2 
concentration dependent reduction in the lag phase,23 we observed no statistically significant 
effect on the lag phase. A key difference between the two studies is that we elected to use small 
borosilicate beads in each well to mix our aggregation reactions during the ThT assays. This is 
known to enhance A aggregation and provide more reproducible aggregation rates.74 As a 
result, our aggregation reactions proceeded much more rapidly in comparison with Gu and Viles. 
We elected to use this protocol as without the beads our rates of aggregation were too variable to 
perform a statistical analysis of kinetic parameters, even without the addition of H2O2.  
 In these studies, the similarities in the lag-phase associated with the presence of up to 3.0 
mM H2O2 suggest that oxidation of Met35 is not pivotal in the initial formation of the critical 
nucleus associated with fibril formation under our experimental conditions. The critical nucleus 
associated with Aβ fibrillization is often considered to be a small oligomer.75–77 While cross-
linking methods to stabilize small Aβ oligomers have demonstrated that Aβ40 forms an 
equilibrium distribution of monomers, dimers, trimers, and tetramer formation, isolated 
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Aβ40Met35[O] only formed dimers, as determined by ESI-MS.78,79 However, co-incubation of 
Aβ40 and Aβ40Met35[O] resulted in trimer and tetramer formation with statistically random 
incorporation of Aβ40Met35[O] into oligomers. This heterogenic mixing is the scenario that is 
applicable to our experimental setup as increasing H2O2 concentration resulted in a gradual 
increase in Aβ40 oxidation at Met35, maxing out at ~50-65%. Taken together, it appears that for 
homogenous systems of oxidized Aβ Met35 plays a large role in the initial oligomerization, but 
under heterogenous systems of Aβ40 and Aβ40Met35[O] oligomerization on-pathway to fibril 
formation can still proceed. 
 Despite the lag phase of aggregation being predominately unaltered in the absence of 
lipids, at large enough H2O2 concentrations (at least 6.0 mM) the relative slope of the growth 
phase, associated with fibril growth of Aβ40, was significantly reduced indicating that the 
addition of monomeric Aβ40 to the terminal ends of fibrils is altered. Since the extent of oxidized 
Aβ40 varies with increases in the oxidative environment, representing a higher population of 
Aβ40-Met35[O] to Aβ40, the reduction in fibril growth could reflect a lower affinity of Aβ40-
Met35[O] for fibril ends. This is consistent with experiments in which the aggregation of 
monomeric Aβ40-Met35[O] was less efficiently seeded by the addition of pre-formed fibrils.23 
The addition of monomeric Aβ to fibril ends has been proposed before to proceed through a two-
step “dock-lock” mechanism80–82 with the C-terminal hydrophobic residues having a 
conformational preference for the initial docking stage.83 Since Met35 is the only observable 
modification to Aβ40 determined by MS and 1H NMR, it is possible that oxidation of Met35 is 
inhibiting the ability of Aβ40 to dock to fibril ends successfully. However, this is difficult to 
ascertain as the reduction of fibril growth at 6.0 mM H2O2 may also reflect the underlying fibril 
structure, as our AFM and CD analysis indicated that a distinct, polymorphic fibril was observed 
2. Hydrogen peroxide modifies Aβ-membrane interactions   
with implications for Aβ40 aggregation  66 
under this condition. That is, the docking and locking mechanism may be distinct as the 
underlying fibril structure is likely different as discussed below. 
 The altered morphology observed by AFM and CD spectral differences associated with 
fibrils formed with 6.0 mM H2O2 suggest a unique fibril structure. Several lines of evidence 
support that oxidation of Met35 could promote a fibril polymorph. Intermolecular interactions 
between Met35-Met35 found in hydrophobic domains have been observed for two-fold84 and 
three-fold symmetric fibrils.85 Cryo-EM resolved structures demonstrating an LS-shaped motif 
placed Met35 in one of three stabilizing hydrophobic clusters. Gremer et al. proposed that these 
Met35-Met35 interactions occur along the fiber axis instead of across the fibril axis as previously 
thought.86 Therefore, Aβ40-Met35[O] with significant alterations to its dipole moment and 
hydrophobicity72,87 would likely not be incorporated into these types of fibril structures as easily. 
NMR structures of pure Aβ42-Met35[O] fibrils have been obtained in which Met35[O] is facing 
away from the hydrophobic core making it solvent exposed.35 In addition, solution state NMR 
studies suggest that the more solvent exposed Met35[O] of Aβ40 or Aβ42 reduces hydrophobic 
and electrostatic associations involved in fibril formation.29  
 The presence of a distinct fibril polymorph might suggest unique oligomeric precursors. 
Just as structural changes of Aβ are hypothesized to be the driving force for aggregation and 
subtle environmental factors can result in unique fibril structures,84,88 one could envision that the 
ratio of Aβ40-Met35[O] to Aβ40 would influence the formation of both off-pathway and on-
pathway oligomers. However, evaluation of oligomer morphology by AFM did not result in any 
observable differences at a morphological level. Time resolved CD spectroscopy did suggest that 
transitory secondary structural elements associated with A40 aggregation was altered at 6.0 mM 
H2O2. From the absence of H2O2 to 1.0 mM H2O2, evidence of an α-helical intermediate was 
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observed, but this was not apparent at 6.0 mM H2O2 despite the similarities in the lag phase. Aβ 
α-helical intermediates on-pathway to fibril formation have been observed via Raman89 and CD 
spectroscopy.90 The NMR study of monomeric Aβ40 in SDS micelles28 and aqueous65 
environments suggested that the structure of monomeric Aβ40 adopts helical conformations. 
Met35 oxidation specifically disrupts a helical region of Aβ spanning from residues 28-36.28 In 
light of the unique fibril structure associated with fibrils formed in the presence of 6.0 mM H2O2, 
it is possible that the oligomers observed under these different conditions were structurally 
different despite being similar in size.  
 Lipid membranes are known to influence the aggregation of Aβ,71 and this is highly 
sensitive to membrane composition.43,71,91 As a result, we aimed to determine how oxidative 
environments influenced A aggregation in the presence of lipid membranes of TBLE. In the 
absence of H2O2, the addition of TBLE LUVs increased the lag-phase as a function of 
peptide/lipid ratio. We then introduced oxidizing environments to a standardized ratio of TBLE 
LUVs and Aβ40. Our observations established that increasing H2O2 concentration reduced TBLE 
LUV’s effect on Aβ40 fibrillogenesis, resulting in similar aggregation profiles for A in 6.0 mM 
H2O2 in the presence and absence of TBLE. A potential explanation is that binding of A to 
TBLE LUVs effectively retards aggregation, but the affinity of A is reduced as Met35 is 
oxidized. As the affinity of A for the TBLE is reduced due to oxidation, the impact of TBLE 
LUVs on aggregation would decrease, and aggregation would proceed in a manner similar to the 
condition when the LUVs are absent. To test this assertion, PDA assays were performed that 
confirmed that increased H2O2 concentration directly correlated with decreased Aβ40 interaction 
with TBLE LUVs.  
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 Due to hydrogen peroxide’s ability to oxidize Aβ40 and TBLE-LUVs simultaneously, we 
sought to distinguish the relative contribution of peptide and lipid oxidation on the reduced 
binding interaction by systematically performing PDA assays with varying combinations of 
oxidized and un-oxidized components. This is important as Aβ binding to cellular membranes 
represents a key phenomenon in assessing cellular susceptibility to Aβ-induced toxicity.41 
Interestingly, Met35 oxidation increased the affinity of Aβ40 for TBLE membranes that were not 
oxidized; whereas, lipid peroxidation reduced the ability of Aβ40 to bind lipids. There are several 
physicochemical possibilities as to why Met35 oxidation increased the affinity of Aβ40 for lipid 
membranes. The methionine sulfoxide side chain is stiffer and more polar compared to 
methionine, and the hydropathy index of methionine sulfoxide is similar to that of lysine,92 
which is known to play a role in membrane protein anchoring,93 cell-penetrating peptides,94 and 
antimicrobial peptides.95 These chemical changes could enhance the affinity of Aβ40-Met35[O] 
with membranes via stronger interactions with polar and charged lipid head groups. Regarding 
the role of lipids, lipid peroxidation is known to rigidify membranes. Interestingly, alteration in 
membrane rigidity correlated with the ability of Aβ40 to bind and damage supported TBLE 
bilayers.96,97 Collectively, our results suggest that the affinity of Aβ for cellular membranes 
would depend not just on intrinsic factors associated with the peptide, but also environmental 
factors. 
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3. Acetylation of Aβ40 alters aggregation in the presence and absence of lipid 
membranes 
One characteristic of Alzheimer’s disease (AD) pathology is the formation of 
extracellular senile plaques comprised of the peptide β-amyloid (Aβ). Aggregation of Aβ is a 
complex nucleation-dependent polymerization process involving the creation of a variety of 
metastable intermediates that can be on-pathway towards fibril formation or off-pathway towards 
amorphous or annular aggregates. An essential feature of the aggregation of Aβ to fibril 
aggregates is the formation of a β-sheet hairpin which is stabilized by a salt bridge between D23 
and K28. Recent evidence has demonstrated that the forming of the salt bridge is a critical step in 
the nucleation process. Lysine-16 has also been implicated in participating in the intermolecular 
formation of salt bridges between fibril strands. Lysine’s in general are involved in protein-
membrane interactions between the cationic lysine and anionic lipid headgroups, and it is this 
general interaction of Aβ with membranes that is proposed to be a toxic mechanism of AD. In 
this work, we explored the role of lysine’s positive charge in the aggregation of Aβ40 in the 
presence and absence of membranes through its removal via acetylation. Here, we report that 
lower levels of acetylation, primarily affecting K16, has minor effects on the fibril formation but 
reduces oligomerization of Aβ40 while higher levels of acetylation involving K16 and K28 
inhibits fibril formation and further reduces oligomerization. However, in the presence of total 
brain lipid extract (TBLE) acetylated Aβ was observed to interact less with the membrane but 
was still able to form fibrils and under extensive levels of acetylation promoted the formation of 
annular aggregates. Our results suggest that in the absence of membranes the aggregation process 
is highly dependent on the electrostatic interactions of K16 and K28, and in the presence of 
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membranes lipids promote the formation of the critical nucleus towards fibril formation in 
addition to promoting secondary aggregation pathways. 
3.1 Introduction: The importance of lysine in the aggregation and membrane 
binding of Aβ 
Two prominent pathological features associated with Alzheimer’s disease (AD), a fatal 
neurodegenerative disorder, are cerebrovascular, diffuse, and neuritic plaques composed 
predominantly of the amyloidogenic peptide amyloid-β (Aβ) and neurofibrillary tangles 
comprised of the protein tau.  These proteinaceous deposits of tau and Aβ are predominantly 
comprised of β-sheet-rich fibrous aggregates termed amyloid fibrils. Aβ aggregation can be a 
multifaceted and complex process that involves a variety of metastable, intermediate species that 
may or may not be directly on-pathway to fibril formation.1The aggregate species that can be 
formed include a variety of soluble Aβ oligomers (AβOs), insoluble protofibrils, and annular 
aggregates.1–3 Beyond the heterogeneity of smaller intermediate aggregate structures, Aβ fibrils 
can form a variety of distinct structure and morphologies, often termed polymorphs, as a result of 
preparatory and/or environmental conditions during the aggregation process.4–6  
Specific domains or amino acids within the Aβ peptide appear to play a prominent role in 
dictating the rate of aggregation and the resulting aggregate morphologies.7 For example, 
specific regions within the Aβ peptide have been implicated as being particularly 
amyloidogenic.7–10 Using site-directed spin labeling electron paramagnetic resonance, two β-
strand forming domains in Aβ were identified (residues11–21 and 29–39, respectively) that were 
separated by a β-turn.11 NMR studies further support the two β-strand regions separated by a β-
turn motif in a number of fibril structures.12–14 Various fragments of Aβ display different 
propensities to aggregate.7 For example, the first β-strand forming stretch of Aβ also contains a 
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hydrophobic core (residues 16–21) with enhanced amyloidogenic properties.15 Furthermore, a 
number of point mutations associated with familial forms of AD clearly alter aggregation rates 
and aggregate morphologies.16 
Lysine is of interest as it contains a cationic charge at the end of an aliphatic chain. There are 
two lysines in Aβ: lysine-16 (K16) and lysine-28 (K28). Electrostatic interactions facilitated by 
these two lysines in Aβ have been suggested by many to play an essential role in Aβ folding, 
nucleation, oligomerization, fibril formation, and toxicity.17,18 Specifically, a salt bridge forms 
between D23 and K28 that stabilizes a β-turn in a variety of fibril structures.18–20 K16 is the first 
amino acid of the previously mentioned hydrophobic core. Additionally, K16 can be involved in 
intermolecular salt bridge formation in some fibril structures of Aβ;18,21 however, K16 is solvent 
exposed in other fibril structures.22 Beyond fibril formation, lysine residues are involved in 
oligomer formation, as substituting alanine for each lysine altered Aβ assembly and highlighted a 
role of K16 in Aβ toxicity.23 
In addition to playing a role in Aβ aggregation, lysines play a prominent role in the 
interaction of Aβ with lipid membranes. In general, lysine plays an important role in facilitating 
a variety of peptide-membrane interactions, as it  contains the ability to electrostatically interact 
with charged lipid headgroups while the alkyl chain allows for hydrophobic interactions within 
the lipid tails.24Interaction with cellular membranes, comprised predominately of lipid bilayers, 
can heavily influence Aβ aggregation,25 potentially promoting unique aggregation pathways,26–28 
nucleating aggregation,29–34 and/or promote/stabilize specific Aβ aggregate species.26,32,35,36It is 
even suggested that the binding of Aβ to the plasma membrane is a key step in Aβ toxicity.37,38 A 
variety of model lipid membranes alter Aβ conformation and exert enormous influence on the 
aggregation state, but the exact impact of lipids on Aβ aggregation is specific to membrane lipid 
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composition.39In addition to influencing Aβ aggregation40,41 Aβ can directly damage cellular 
membranes, resulting in membrane dysfunction through altered mechanical properties42 and/or 
the formation of discrete pores.32,35,43 While lipid composition and biophysical properties of 
membranes play a role Aβ/lipid interactions, physicochemical properties of the residues within 
Aβ also play a role in the surface interactions.16,44 For example, disease-related point mutations 
within Aβ alter the aggregate species observed on model lipid membranes, with hydrophilicity 
and  electrostatic properties of specific amino acids playing a key role.16 
Here, our aim was to understand how acetylating lysine alters Aβ40 aggregation in the presence 
and absence of lipid membranes. Aβ40 was acetylated by exposure to sulfo-N-
hydroxysulfosuccinimide acetate (NHSA) producing acetylated K16 (AcK16) and K28 (AcK28). 
The lipid system used was total brain lipid extract (TBLE), which contain a physiologically 
relevant mix of lipid components. In the absence of lipid vesicles, acetylation of Aβ40 reduced 
both oligomerization and fibrillization, with extensive acetylation resulting in complete 
inhibition of fibril formation. However, the presence of TBLE lipid vesicles appeared to invoke a 
distinct aggregation mechanism, resulting in fibril formation even when Aβ40 was extensively 
acetylated.   
 
3.2 Materials and Methods 
 3.2.1 Peptide Preparation — Synthetic Aβ40 (Invitrogen, 1 mg) was equilibrated to room 
temperature for 30 mins. Aβ40 was dissolved in10% NH4OH(w/v) to acquire an alkaline stock 
solution of Aβ40 (0.5 mg/mL). The stock solution was unperturbed for 10 min followed by 5 min 
of bath sonication. The Aβ40 stock solution was aliquoted and snap frozen. Aliquots were 
lyophilized overnight and stored at -80 °C until the day of experimentation. For experiments, 
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individual aliquots of Aβ40 were equilibrated to room temperature. An alkaline solution, 60 mM 
NaOH(aq), was used to solubilize Aβ40 (target concentration of 1.5 mg/mL), creating what is 
referred to as the Aβ40•NaOH solution. The Aβ40•NaOH solution was incubated at room 
temperature for 10 min, after which it was gently pipette mixed. The actual concentration of the 
Aβ40•NaOH solution was measured (NanoDrop, ThermoScientific) via absorbance at 280 nm 
with an extinction coefficient of 1440 M-1 cm-1. The pH of the Aβ40•NaOH solution was 
controlled to be ≥ 11.23. For all experiments, the Aβ40•NaOH solution was diluted into a 20 mM 
HEPES 150 mM NaCl buffer, pH = 7.23. 
 3.2.2 Mass Spectrometry  — For the MS experiments, the Aβ40•NaOH solution was 
divided into 10 μg aliquots. These aliquots were diluted in the HEPES buffer and then treated 
with NHSA at increasing molar ratios of NHSA:Aβ40. Samples were allowed to incubate at room 
temperature for 1 h before the NHSA reaction was quenched with 1 M TrizmaTM (Sigma 
Aldrich, St. Louis, MO). All samples were snap-frozen and lyophilized overnight. The following 
day, samples were dissolved in 1 M acetic acid containing 0.5 mg/mL of pepsin (10:1 pepsin: 
Aβ40). Samples were left overnight protected from light and incubated at room temperature. On 
the 3rd day samples were analyzed via LC-MS (Thermofisher Scientific Q Exactive Mass 
Spectrometer, an LC-MS/MS with orbitrap). To remove residual salts, chromatography utilized a 
C18 column (ZORBAX RRHD Eclipse XDB 80Å C18, 2.1 x 100 mm, 1.8 µm; Agilent, Santa 
Clara, CA) and a mobile phase of 0.1% formic/water (v/v) (%A) and 0.1% formic 
acid/acetonitrile (v/v) (%B) with a gradient of 5%B for 0-2 min, 40%B for 5 min, 50%B for 6 
min, 95%B for 7-8 min, and 5% B for 8.5-10 min with a flowrate of 300 μL/min. A full scan was 
performed for the mass charge range of 200-2000 m/z with a resolution of 70,000 and a 
resolution of 17,500 for the Top 5 method that was used. Mass spectrum analysis was performed 
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using Proteome DiscoveryTM to determine the percent abundance of AcK16 and AcK28. This 
was carried out by comparing lysine specific fragments of Aβ40 to the same peptide fragments 
containing a 43.05 Da mass shift, for all charge states. 
 3.2.3 Thioflavin-T Fluorescence Assay (ThT) — Monitoring fibril formation was achieved 
with thioflavin T (ThT; Sigma Aldrich, St. Louis, MO) assays. Assays were carried out in a 
Costar 96-well black clear flat bottom plate. The Aβ40•NaOH solution was added to 20 mM 
HEPES 150 mM NaCl solutions containing 3 molar equivalents of ThT to Aβ40 and varied molar 
equivalents of NHSA to Aβ40 at a pH of 7.23. The resulting solutions contained 20 μM Aβ40 and 
the addition of 0.16, 0.32  0.50 1.00 1.50 mM NHSA. Additionally, a 3 mm borosilicate bead 
was introduced to facilitate homogeneous mixing across wells.45 The assay plate was sealed with 
plate tape, and incubated at 37 °C for 24 h on a SpectraMax M2 Multi-Mode plate reader 
(Molecular Devices, Sunnyvale, CA). Fluorescence intensities were measured in 5 min intervals 
at excitation and emission wavelengths of 440 nm and 484 nm, respectively, with shaking in 
between reads. Assays performed in the presence of TBLE were performed in the same manner 
with the addition of TBLE vesicles prepared as described below. 
 Data analysis was performed utilizing GraphPad Prism 6 was to average replicates, 
perform baseline corrections, and error analysis reported as the standard error mean (SEM). 
Additionally, through the use of a Boltzmann sigmodal function (Equation 1) kinetic parameters 
such as the nucleation time, commonly referred to here as lag-phase (tlag), was empirically 
obtained by fitting the individual traces of ThT curves.46,47 
  (Eq. 1) 
Utilizing GraphPad Prism 6 the initial lag-phase and plateau regions of the curves are defined by 
linear fits where the initial fluorescence and slope are defined by, yi and mi, and the final 
3. Acetylation of Aβ40 alters aggregation in the presence and absence 
of lipid membranes  82 
fluorescence and slope as, yf and mf, respectively. The time to reach the half maximum of the 
curve is defined by xo and the elongation time constant of the growth phase is defined as τ. As a 
nonideal sigmodal function, no constraints were applied. A least squares fitting operation was 
then performed for a maximum iteration limit of 1000. The lag-phase time was calculated from 
the kinetic parameters, tlag=xo-2τ. The slope of the growth phase is associated with the growth of 
fibrils. The slope was calculated by normalizing the ThT traces to the mean maximum response 
of control group (no NHSA added) within each independent experiment for comparison across 
experiments. To obtain the relative slope of the growth phase, Rslope(h
-1) the linear fits of the 
growth phase were performed by defining the boundaries of the fit to only include the linear 
region between the lag-phase and the plateau region as visually determined for each ThT curve. 
The maximum signal of fluorescence at steady state was calculate using a linear fit over the 
plateau region of the sigmodal curve. This was accomplished by adjusting the starting point of 
the data to be fit and moving it further back to optimize the r2 value. Initial starting point points 
were visually determined to be near the inflection point where the sigmoidal curve enters the 
plateau region. The fits were performed from these starting points to the end of the data set. Once 
the boundaries were defined, the average fluorescence signal within this plateau region was 
determined. For comparison between trials, these were converted to the relative fluorescence at 
steady state (RFss) by dividing each value by the control experiment (no NHSA for that 
experiment). All kinetic parameters were then averaged from triplicates of independent 
experiments to determine the mean ± SEM. Significance was reported as greater than 95% 
confidence calculated using a standard Student’s T-test to determine variations in parameters 
across varied NHSA concentrations. 
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3.2.4 Lipid Vesicle Preparation — Total lipid brain extract (TBLE; Avanti Polar Lipids, 
Alabaster, AL) was dissolved in chloroform at 25 mg/mL and divided into 5 mg aliquots. 
Chloroform was removed in vacuo, producing a transparent film, and each aliquot was stored at -
20°C. A 5 mg amount of TBLE was hydrated with a 20 mM HEPES 150 mM NaCl buffer, pH = 
7.23, and allowed to incubate for 30 mins at 60°C and 1400 rpm in a Thermomixer. Lipid 
samples were vigorously pipetted and scraped to remove all traces of TBLE from the walls of the 
centrifuge tube, after which the samples were put through 7 freeze-thaw cycles and 30 min of 
bath sonication at 37°C. Lipid stocks were again heated to  60°C before being extruded through a 
100 nm polycarbonate membrane filter. Resulting lipid solutions were kept at 37°C before being 
diluted into a HEPES solution at a final concentration of 0.432 mg/mL within a 96-well plate for 
a protein to lipid ratio of 30:1. 
 3.2.5 Ex situ Tapping Mode Atomic force microscopy (TMAFM) — Incubations of Aβ40 
(20 µM) were performed in a similar manner to previous ThT assays with the same 
concentrations and ratios of Aβ40 to NHSA. Solutions were incubated at 37°C and shaken and 
read at the same intervals as previous ThT assays, however at the time points of 0, 1, 3, 5, 7, 8, 9, 
11, and 24 h the 96-well plate was removed from the plate reader and two 2 μL samples were 
taken from each solution. The experiment was done in this manner in order to track the progress 
of Aβ aggregate formation. Once samples were taken, they were allowed to incubate for 1 min 
before being washed with 200 μL of 18 MΩ water for one sample and 100μL of 18 MΩ water 
for the other sample of the same variable. Samples were dried with compressed air immediately 
after being washed. After taking samples, the plate was returned and incubated until the next 
time interval. Samples were imaged via atomic force microscopy (AFM) under tapping mode on 
a Nanoscope V Multimode (Veeco, Santa Barbara, CA) with a closed-loop vertical engage J-
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scanner. Cantilevers used for images were a diving-board-shaped silicon oxide cantilever with a 
resonance frequency of ~300 kHz and a spring constant of 40 N/m (Budget Sensors).  
 3.2.6 TMAFM Image Analysis — Images were processed utilizing Matlab equipped with 
the image processing toolbox (MathWorks, Natick, MA).48 To correct for background curvature, 
height images were flattened using a 2nd polynomial flattening algorithm. To aid in automatically 
identifying individual aggregates, AFM images were converted into binary maps after 
establishing a height threshold of 1.0 nm. Individual aggregates were determined from the binary 
maps using a recognition algorithm. Physical features of individual aggregates (e.g., height, 
volume, diameter, shape factor, length, aspect ratio, length, and area covered) were measured. 
Average heights of fibrils were determined by measuring the fibrils along their contour length 
while excluding any cross over regions of overlapping fibrils. The range of fibril contour length, 
or the spread of fibril heights, was calculated as the interquartile range which involves taking the 
median of the lower and upper of a given dataset. Populations of oligomers and fibrils, along 
with the percent area covered by fibrils, were plotted using GraphPad Prism 6 to average across 
replicates and perform error analysis reported as a standard error mean (SEM).  
 3.2.7 Preparation of TBLE/Polydiacetylene Vesicles (PDA) — Separately 8.4 mg of 
10,12-tricosadiynoic acid (PDA) (GFS Chemicals, Columbus, OH) and 5.0 mg of TBLE was 
dissolved in a 1:1 chloroform: ethanol solution. The two were combined in a glass vial at a 60:40 
mass ratio of PDA to TBLE, and solvents were removed in vacuo to produce a TBLE/PDA film. 
This film was hydrated with 8 mL of the same 20 mM HEPES 150 mM NaCl buffer, pH = 7.23, 
and temperature of 75°C. The solution was probe sonicated at 180 W continuously for 10 min. 
The resulting solution was stored protected from light in a 4°C fridge overnight. The following 
day the TBLE/PDA solution was allowed to reach ambient temperature before transferring it to a 
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100-mL beaker. The solution was stirred at 300 rpm for 10 min under cover of a black box 
adapted with a TLC lamp that irradiated the solution at 254 nm for the full length of time. PDA 
assays were performed in a Costar 96 black clear flat bottom well plate with the addition of 3 
mm borosilicate glass beads. Peptide-lipid interactions were observed fluorescently at room 
temperature with excitation and emission wavelengths of 485 nm and 560 nm utilizing a 
SpectraMax M2 Multi-Mode plate reader (Molecular Devices, Sunnyvale, CA). Data analysis 
was performed by averaging triplicates and performing baseline-corrections all within the 
GraphPad Prism 6 software suite 
 3.3 Results 
 3.3.1 Lysine-16 is preferentially acetylated over lysine-28.  To determine the extent at 
which K16 and K28 were accessible for acetylation and determine experimental conditions under 
which the impact of acetylation on aggregation could be studied, Aβ40 (20µM) was exposed to 
NHSA, an established agent for acetylating primary amines.49,50 Aβ40 was treated with varying 
concentrations of NHSA ranging from 0.02 mM to 2.5 mM (resulting in a range of peptide to 
NHSA molar ratios of 1:1 to 1:125). As there are two lysines in Aβ40 that can be acetylated (K16 
and K28), Aβ40 was digested with pepsin to generate peptide fragments containing only one of 
the lysines so that the extent of acetylation of each discrete lysine could be determined by MS.  
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 The percent of acetylated K16 (AcK16) and K28 (AcK28) was determined by comparing 
the abundance of these peptide fragments containing just one lysine that were acetylated or not 
(Figure 3.1). When no NHSA was added 
to A40, no acetylation of lysine was 
observed. At lower concentrations of 
NHSA, ranging from 0.02 mM to 0.16 
mM, K16 is preferentially acetylated over 
K28 with K16 acetylation being 5-3 × 
more abundant than K28 (Figure 3.1B). 
With the 0.16 mM treatment of NHSA, 
AcK16 and AcK28 only represented 47% 
and 14% of the total Aβ acetylated 
respectively. Effectively, these lower 
concentration treatments of NHSA 
resulted in conditions at which K16 was 
the predominately acetylated lysine; 
however, most of the available lysines 
(both K16 and K28) were not acetylated. 
At NHSA concentrations of 0.50 mM, 
75% of K16 was acetylated, while 35% of K28 was acetylated, resulting in a condition in which 
the vast majority of A was acetylated with AcK16 being the most abundant form (~2×). Further 
increasing the concentration of the acetylating agent to 1.0 mM and 1.5 mM produced an 
increase in the acetylation of K28 to about 60-75% and reduced the ratio of AcK16:AcK28 to 
 
Figure 3.1. Acetylation of K16 occurs more readily 
than K28 (A) MS analysis of K16 and K28 specific 
peptide fragments reported as the percent abundance 
of acetylated to unacetylated lysine. (B) Ratio of AcK16 
to AcK28 over increasing ratios of NHSA to Aβ40. 
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about 1:1 at 1.5 mM NHSA. While AcK16 and AcK28 was observable with all treatments with 
NHSA, the NHSA concentrations of 0.02 mM to 0.50 mM represent a regime in which K16 is 
predominantly more acetylated than K28; whereas, concentrations of 1.0 mM and above of 
NHSA both K16 and K28 are acetylated to similar and significant extents.   
3.3.2 Acetylation of Aβ40 extends the lag phase and extent of aggregation. Having 
established the extent of acetylation of K16 and K28 exposed to varying amounts of NHSA, we 
next determined the impact of AcK16 and AcK28 on the aggregation of Aβ40. ThT assays were 
performed with 20 µM Aβ40 that had been exposed to increasing concentrations of NHSA 
(Figure 3.2). 
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Figure 3.2. ThT assays investigating the 
impact or acetylation on Aβ40 aggregation. 
(A) Representative ThT curves for one of 
three independent experiments performed at 
37°C, all at concentrations of 20 μM Aβ40 
(green), with increases in NHSA 
concentrations to 0.16 mM (blue), 0.32 mM 
(purple), 0.50 mM (pink), 1.0 mM (orange), 
and 1.5 mM (red). Non-linear sigmoidal 
lines of best fits represented as continuous 
lines calculated using Equation 1. Kinetic 
parameters of (B) lag-phase time, tlag(h), and 
(C) slope of growth phase Slope(h-1) were 
extracted from Equation 1 for all 
experiments and shown as the mean ± SEM. 
(D) Normalized maximum response of the 
steady state region of ThT curves, RFss, 
calculated by averaging the plateau region 
then normalizing all variables to their 
respective control. Data shown as mean ± 
SEM of the normalized raw fluorescence 
signals of three independent experiments; 
(*) P ≤ 0.05, (**) P ≤ 0.01, (***) P ≤ 0.001, 
and (****) P ≤ 0.0001. 
 
 
In general, increasing acetylation of Aβ40 inhibited aggregation. That is, as the concentration of 
NHSA increased, the lag phase extended and the total extent of fibrillization decreased. The 
addition of 0.16 mM and 0.32 mM NHSA did not significantly change the lag phase associated 
with Aβ40 compared to control (Aβ40 that was not exposed to NHSA).  Aβ40 in the absence of an 
NHSA treatment, with 0.16 mM, or 0.32 mM treatment of NHSA exhibited similar lag-phases of 
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6.8 ± 0.16 h, 6.4 ± 0.22 h, and 7.0 ± 0.17 h respectively (Figure 3.2B), and the relative slope of 
the growth phase, Rslope (h
-1), was also not significantly changed (0.40 ± 0.058 h-1, 0.33 ± 0.037 
h-1, and 0.27 ± 0.046 h-1 respectively, Figure 2C). Treatment with 0.16 mM, 0.32 mM, and 0.50 
mM NHSA reduced the total extent fibrillization as the relative fluorescent unit signal of the 
steady-state plateau region, RFss, of the ThT curve by 23%, 45%, and 53% respectively (Figure 
3.2D). Increasing the concentrations of NHSA to 0.50 mM resulted in a statistically significant 
extension of the lag phase, 7.7 ± 0.13 h. In addition, the slope of the growth phase at 0.50 mM 
NHSA significantly deviate from the control, 0.15 ± 0.040 h-1 (Figure 2C), and the total extent of 
fibril formation (measured as relative fluorescence at steady state) was reduced by 58%.  Finally, 
treatment with 1.0 mM NHSA and 1.5 mM NHSA completely suppressed fibril formation over 
the 20 h ThT assay; although, there is a hint of a potential fibril nucleation event after ~ 18 h.  As 
such, accurate lag phase and growth phases could not be determined; however, the relative 
fluorescence at the end of experiment is less than 20% of the control for both conditions. 
3.3.3 Acetylation of Aβ40 inhibits fibril formation and oligomerization. While the ThT assays 
demonstrate that acetylation of lysine via exposure to NHSA reduce fibrillization of Aβ40, these 
assays do not provide information concerning the potential of acetylation to promote 
polymorphic fibril structure or AβO formation. In light of previous observations that substituting 
lysine in A with alanine results in altered fibril morphology,23 we incubated A40 under the 
exact same conditions as used in the ThT assays and sampled these solutions at multiple time 
points for AFM analysis. Beyond looking at fibril morphology, this has the added benefit of 
allowing for the assessment of AO formation. To analyze the population and dimensions of A 
fibrils and AOs, criteria based on aggregate morphologies were used for automated image 
analysis.48 AO were defined in AFM images as being larger than 1 nm in height, having an 
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aspect ratio of between 1.0 and 2.5 (indicating a non-fibrillar morphology), and occupying a 
surface area less than 9500 nm2. The surface area criteria were based on our observation that the 
smallest fibrils occupied a surface area of ~ 10,000 nm2 and that oligomers occupied an area 
typically 5 times smaller than this.  Fibrils were identified as aggregates that were at least 1 nm 
in height with an aspect ratio greater than 2.5 and occupying a surface area or at least 10,000 
nm2. Upon solubilization, an initial aliquot of A40 was sampled for all conditions (effectively 
time point 0 h), and no aggregates were observed.  
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Figure 3.3. Atomic force microscopy images of Aβ40 aggregates as a function of increasing 
acetylation and time.  Representative ex situ AFM images sampled at multiple time points over 
20 h of Aβ40 (20μM) at NHSA concentrations of 0.0 mM, 0.16 mM 0.32 mM, 0.50 mM, 1.0 mM, 
and 1.5 mM. Depositions of Aβ40 imaged at 5x5 μm scan size on a mica substrate, shown here as 
2.5x2.5 μm zoomed in images. Color scale ranges from -5 nm to 10 nm. 
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Figure 3.4. AFM image analysis of the 
impact of acetylation on Aβ40 aggregate 
populations and morphologies. (A) 
Population of oligomers per μm2 over time 
determined by image analysis. Oligomer 
counts divided by the total area of the image 
analyzed. (B) Percent area covered by fibrils 
determined by filtering out aggregates with 
an area less than 95 nm2, converting images 
to binary maps, and dividing by the total 
image area. (A, B) Bar graphs shown as 
mean ± SEM (C) Histogram of oligomeric 
heights measured over the entire 20 h time 
course of the experiment for Aβ40 (20μM) at 
NHSA concentrations of 0.0 mM, 0.16 mM 
0.32 mM, 0.50 mM, 1.0 mM, and 1.5 mM. 
Red dashed line represents the oligomeric 
height of unacetylated Aβ40 at 2.5 nm.   
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Based on AFM images and consistent with the ThT assays, increasing acetylation of A40 
impaired aggregation (Figure 3.3). AO growth was quantified by counting the number of 
discrete oligomers per unit area observed on mica (Figure 3.4A); fibril growth was quantified by 
the percent of the mica surface covered by fibrils (Figure 3.4B). This approximation was used to 
quantify the extent of fibril formation due to fibril bundling and a heterogeneity in length, 
making it difficult to manually, or with an algorithm, determine the exact numbers of fibrils. 
When non-acetylated A was incubated, a large population of oligomers were observed within 3 
h with a peak population appearing between 5-7 h, as measured by the number of AOs per unit 
area (Figure 3.4A). Fibrils appeared after 7 h of incubation, and the fibril density on the mica 
surface steadily increased, as measured by the % area of the surface occupied by fibrils (Figure 
3.4B). The appearance of fibrils coincided with a steady decline in the AβO population.  
 When treated with NHSA concentrations of 0.16 mM, 0.32 mM, and 0.5 mM, AOs also 
appeared after 3 h of incubation; however, the AO population was significantly reduced in an 
acetylation-dependent manner (Figure 3.3 and Figure 3.4A). With all three of these NHSA 
treatments, fibrils were still observed at later time points.  For both 0.16 mM and 0.32 mM 
concentrations of NHSA, fibrils could be observed after 7 h of incubation, but fibrils were not 
observed by AFM for A40 treated with 0.5 mM NHSA until after 9 h of incubation (Figure 3.3 
and Figure 3.4B). The density of fibrils observed on mica was also decreased as a function of 
acetylation (Figure 3.4B). Consistent with the ThT assays, treatment with NHSA concentrations 
of 1.0 mM and 1.5 mM resulted in no observable fibrils over the 11 h incubation time. In 
addition, the number of AOs observed at any given time point was greatly reduced (~20 times), 
suggesting that extensive acetylation arrests A40 aggregation at the oligomeric phase. It should 
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be noted that the detection limit of AOs associated with this AFM analysis is likely on the order 
of octamers. That is, smaller AOs may still have formed, but would be difficult to observe with 
this assay. Hexameric and smaller AOs have been observed for A40 in which the lysines have 
been substituted for with alanines.23 With that being said, size analysis demonstrates that 
reaching a condition in which A40 is significantly acetylated results in smaller and fewer AOs. 
Specifically, AOs formed without NHSA treatment or with NHSA treatments of 0.32 mM or 
less resulted in oligomers of with a broad height distribution with a mode of ~1.5-3.5 nm (Figure 
3.4C). NHSA treatments of 0.5 mM or greater resulted in oligomers that had a mode height of 
~1-1.5 nm (Figure 3.4C). As the size of AOs observed under a specific condition did not 
change as a function of time and so few oligomers were observed at large NHSA treatments, the 
height histograms presented were compiled over all time points.  
 To determine if acetylation promoted unique fibril polymorphs, morphological features 
of fibrils grown under the different treatments of NHSA were determined by AFM image 
analysis (Fig 5).  Height profiles were taken perpendicular to the axis of each fibril for Aβ40 
fibrils formed at NHSA concentrations of 0.0 mM , 0.16 mM, 0.32 mM, and 0.50 mM (Figure 
3.5A). The 1.0 mM and 1.5 mM NHSA condition were not analyzed as fibrils were not observed. 
Profiles were taken in a manner to avoid fibril crossings in order to better represent the height 
scale of single fibril species. The fibril height profiles of Aβ40 at 0.0 mM , 0.16 mM, 0.32 mM, 
and 0.50 mM NHSA concentrations all had a mode fibril heights of ~2.5 nm (Figure 3.5A), 
suggesting that the fibrils formed under these conditions were not polymorphic. As fibril height 
can vary along the contour of the fibrils, the average height along fibril contour of every 
individual fibril was determined. As fibril heights did not appear to vary as a function of time, 
data time points of 7 h and beyond were compiled for each variable to produce histograms of the 
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average fibril contour height (Figure 3.5B). The median fibril contour height for NHSA 
concentrations of 0.0 mM , 0.16 mM, 0.32 mM, and 0.50 mM were 2.4 nm, 2.2 nm, 3.1 nm, and 
2.5 nm, respectively; with an interquartile range of 1.0 nm, 0.8 nm, 0.4 nm, and 0.6 nm, 
respectively (Figure 3.5B), confirming the absence of any polymorphic fibril structures for Aβ40 
under these acetylating concentrations. 
 
3. Acetylation of Aβ40 alters aggregation in the presence and absence 
of lipid membranes  96 
 
Figure 3.5. Comparison of fibril aggregates 
of Aβ40 as a function of acetylation. (A) 
Height profiles of representative ex situ AFM 
images of Aβ40 (20μM) at 0.0 mM, 0.16 mM, 
0.32 mM, and 0.50 mM NHSA concentrations 
at 11 h. Colored lines of images correspond 
to adjacent height profiles. Conditions that 
did not produced fibril were excluded (B) 
Histogram of the average fibril height as 
measured along the contour length of each 
fibril for time points of 7 h and greater. (A, B) 
Red dashed-line represents height of 2.5 nm. 
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3.3.4 Exposure to TBLE membranes promotes fibrillization of acetylated A40.  As the 
presence of lipid membranes has been implicated as a modifier of A aggregation,39,51 and 
lysines play a prominent role in peptide/lipid interactions,52–54 we next wanted to determine how 
the presence of lipid membranes modifies the aggregation of Aβ40 under the various acetylating 
conditions. ThT assays were performed in the presence of large unilamellar vesicles (LUV) of 
TBLE. TBLE was chosen as a model system due to its physiologically relevant mixture of 
membrane lipids and its extensive use in studying A membrane interactions.7,16,55,56 In short, 
Aβ40 (20μM) was incubated in the presence of TBLE LUVs at a lipid to peptide ratio of 30:1 (0.5 
mg/mL) under the same experimental and instrumental conditions as the assays performed in the 
absence of lipids. There are examples in the literature of the presence of lipids both 
accelerating57–59or slowing39,60A aggregation. While the lipid composition of the membrane 
plays a role,39,61,62 the preparatory history of A may also influence the A/lipid interaction.56 
With the A preparation protocol used here, TBLE membranes slowed aggregation compared to 
aggregation in the absence of lipids (compare the ThT assay curves of A40 without NHSA 
treatment in Figure 3.2 and Figure 3.6).63 
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Figure 3.6. ThT assays investigating the 
impact or acetylation on Aβ40 aggregation 
in the presence of TBLE LUVs. (A) 
Representative ThT curves of three 
independent experiments of Aβ40 (20 μM) 
(green) in the presence of TBLE LUVs at 
30:1 lipid-peptide ratio (~0.5 mg/mL) at 
37°C for all other variables. Aβ40 was also 
incubated under increasing concentrations 
of NHSA, 0.16 mM (blue), 0.32 mM (purple), 
0.50 mM (pink), 1.0 mM (orange), and 1.5 
mM (red). Lines represent the sigmodal fit of 
calculated from Equation 1. Bar-graphs of 
kinetic parameters of the (B) lag-phase, 
tlag(h), and (C) the slope of the growth 
phase, Rslope(h-1), was determined for all 
variables by extracting values from the line 
of best fit. Values of tlag(h) and Slope(h-1) 
were extracted from three independent 
experiments plotted as the mean value. (D) 
Normalized maximum response of the steady 
state region of ThT curves, RFss, calculated 
by averaging the plateau region then 
normalizing all variables to their respective 
control. Data shown as mean ± SEM of the 
normalized raw fluorescence signals of three 
independent experiments; (*) P ≤ 0.05, (**) 
P ≤ 0.01, (***) P ≤ 0.001, and (****) P ≤ 
0.0001. 
 
 For example, the presence of TBLE extended the lag phase of A40 aggregation ~ 5 h. While 
acetylation associated with NHSA treatment of 1.0 mM or greater completely prevented 
fibrillization in the absence of TBLE vesicles, Aβ40 formed fibrils under all acetylating 
conditions based on the ThT assay curves (Figure 3.6), and this was later confirmed by AFM 
images of these solutions at the end of the ThT assay (Figure 3.7). In the presence of TBLE,  the 
lag-phase decreased with increasing acetylation, with the following lag-phase times exhibited; 
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Aβ40, 9.8 ± 0.67 h; 0.16 mM NHSA, 7.8 ±  0.40 h; 0.32 mM NHSA, 7.2 ± 0.31 h; 0.50 mM 
NHSA, 6.8 ± 0.34 h; 1.0 mM NHSA, 7.1 ± 0.36 h; and 1.5 mM NHSA, 6.8 ± 0.99 h (Figure 
3.6B). This trend suggests that Aβ acetylation promotes the formation of the critical nucleus 
associated with fibril initiation. This is in stark contrast to impact of acetylation in the absence of 
TBLE, in which the lag phase was extended. In addition to the shortened lag phase in the 
presence of TBLE vesicles, acetylating conditions of 0.5 mM, 1.0 mM, and 1.5 mM NHSA all 
exhibited a statistical significance decrease in the slope of the growth phase compared to the 
control; Aβ40, 0.43 ± 0.042 h-1; 0.5 mM NHSA, 0.26 ± 0.026 h-1; 1.0 mM NHSA, 0.17 ± 0.027 h-
1; 1.5 mM NHSA, 0.18 ± 0.031 h-1 associated with A40 acetylation in the presence of TBLE. 
Concomitant with this shortened lag phase, the overall β-sheet load, as measured by relative 
fluorescence at steady state, systematically decreased with increasing acetylated lysine content. 
The reduction in β-sheet formation started with ~20-35% reduction at 0.16 mM NHSA and 0.32 
mM NHSA concentrations to ~60% reduction for 1.0 mM NHSA and 1.5 mM NHSA (Figure 
3.6D).  
 
3.3.5 TBLE promotes unique aggregate morphologies of acetylated Aβ40. While not 
resulting in unique fibril morphologies in the absence of lipids, point mutations in Aβ associated 
with familial forms of AD aggregate into unique polymorphic structures in the presence of TBLE 
bilayers.16 This suggests that acetylation could promote polymorphic fibrils in the presence of 
TBLE, despite not producing polymorphs in the absence of lipids. To determine if acetylated 
forms of Aβ40 produced polymorphic fibrils, Aβ40 (20μM) was incubated in the presence of 
TBLE LUVs at a lipid to peptide ratio of 30:1. After 20 h samples were deposited on a mica 
substrate and AFM image analysis was performed for all conditions. Height profiles of fibrils 
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demonstrated a fibril height of 2.5-3.0 nm (Figure 3.7A), like that observed in the absence of 
TBLE (Figure 3.5A). However, there are several regions along the contour of the fibrils formed 
in the presence of TBLE that appeared thicker. That is, the morphology along the contour of the 
fibril deviated to a greater extent. 
 
 
Figure 3.7 Comparison of fibril morphologies of Aβ40 as a function of acetylation. (A) 
Height profiles of representative ex situ AFM images of Aβ40 (20μM) at 0.0 mM, 0.16 mM, 0.32 
mM, 0.50 mM, 1.0 mM, and 1.5mM NHSA concentrations at 20 h. Colored lines of images 
correspond to adjacent height profiles. (B) Histogram of the average fibril height as measured 
along the contour length of each fibril. (A, B) Red dashed-line represents height of 2.5 nm. 
As a result, the height along fibril contours had a much broader distribution when compared to 
fibrils in the absence of lipids. Median heights of fibrils in the presence of TBLE were 3.6 nm 
(0.0 mM NHSA), 3.3 nm (0.16 mM NHSA), 3.3 nm (0.32 mM NHSA), 3.9 nm (0.50 mM 
NHSA), 2.8 nm (1.0 mM NHSA), and 3.3 nm (1.5 mM NHSA), and the distribution of heights 
defined by the interquartile range were 2.6 nm (0.0 mM NHSA), 2.0 nm (0.16 mM NHSA), 1.9 
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nm (0.32 mM NHSA), 2.0 nm (0.50 mM NHSA), 2.1 nm (1.0 mM NHSA), and 2.1 nm (1.5 mM 
NHSA) (Figure 3.7B). An example of this broadening can be observed for Aβ40 and 0.50 mM 
NHSA in Figure 3.8B. Collectively, it appears that TBLE does not promote a fibril polymorph in 
acetylated Aβ40; however, the increased variation in morphology along the fibril contour may 
indicate that lipids are being incorporated into or decorating the observed fibrils. This does not 
appear to be dependent on acetylation. Rather, it appears to be a consequence of fibril formation 
in the presence of TBLE vesicles.  
 While the morphology of fibrils formed in the presence of TBLE did not appear to be 
altered by acetylation, increased acetylation promoted the formation of annular aggregates in the 
presence of TBLE (Figure 3.7A and Figure 3.8). For conditions of 1.0 and 1.5 mM NHSA, a 
large population annular aggregates formed (2.6 ± 0.4 to 6.4 ± 0.6 per 25 μm2, respectively) that 
were not readily observed in the absence of lipid or with lower levels of acetylation. These 
annular aggregates were considerably thicker than fibrils with heights ranging from ~ 5-10 nm 
(Figure 3.8B). The inner diameter of these annular aggregates ranged from ~60-200 nm with a 
median size of ~114 nm (Figure 3.9B). Many annular aggregates appeared to be strongly 
associated with fibril aggregates as they were co-localized on the mica surface, with some fibrils 
appearing to protrude directly from annular aggregates (Figure 3.9A).   
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Figure 3.8 Acetylation of Aβ40 in presence of TBLE produces annular aggregates. (A) 5×5 
μm representative ex situ AFM images of Aβ40 (20μM) at 1.0 mM NHSA and 1.5 mM NHSA 
concentrations in the presence of TBLE. Boxes illustrating regions of zoomed in images (B) 
Zoomed in 0.5×0.5 μm images of annular aggregates for 1.0 mM and 1.5 mM NHSA. Colored 
lines correspond to height profiles with the red dashed line representing 8.0 nm height. Color 
scale constant for all images. 
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Figure 3.9. Fibrils and annular aggregates 
often colocalize. (A, B) Zoomed in 1.0×1.0 
μm images of annular aggregates and fibrils 
of Aβ40 (20 μM) at 1.5 mM NHSA. (A) Height 
profiles of annular and fibril aggregates. 
Colored line corresponds to colored line of 
image. (B) Representative ex situ AFM 
image showing the range of pore sizes for 
annular aggregates. Color scale is the same 
for all images. 
 
 
 
Figure 3.10. Polydiacetylene 
binding assay of Aβ40 at 
increasing states of acetylation. 
PDA fluorescence response (λEx 
485 nm, λEm 560 nm) time-course 
of Aβ40 (green) interacting with 
PDA/TBLE vesicles, incubated at 
25°C. Aβ40 was additionally 
incubated under increasing 
concentrations of NHSA, 0.0 mM 
NHSA (green), 0.16 mM NHSA 
(blue), 0.32 mM NHSA (purple), 
0.50 mM NHSA (pink), 1.0 mM 
NHSA (orange), and 1.5 mM 
NHSA (red). 
 
3.3.6 Acetylation reduces the affinity of Aβ40 for TBLE membranes. As the presence of TBLE 
vesicles clearly influenced the aggregation of acetylated Aβ40, a polydiacetylene (PDA) lipid 
binding assay was performed to measure the total interaction between Aβ40 and TBLE 
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membranes (Figure 3.10).  Polydiacetylene is a lipid moiety that is easily incorporated into 
vesicles and photo-crosslinked, resulting in hybrid vesicles with enhanced fluorescence in 
response to mechanical stress associated with peptide binding and aggregation. By monitoring 
fluorescence of these vesicles as a function of time, the total interaction of Aβ with the 
TBLE/PDA vesicles can be monitored. Control experiments were performed with the various 
doses of NHSA, and a fluorescent response was not invoked in these control experiments. Upon 
exposure of TBLE/PDA vesicles to Aβ40, the fluorescent signal steadily increases as the peptide 
binds and aggregates on the vesicles. As the extent of Aβ40 acetylation was increased, the total 
interaction between the peptide and vesicles gradually was reduced. As binding to and 
aggregation on the vesicle can both induce PDA response, it is important to interpret this assay 
with the results of the ThT assay in mind. As the shortest lag phase for any condition was ~ 7 h 
as determined by the ThT assay, the PDA response for the first 7 h is dominated by the initial 
binding of Aβ to the membrane. It appears that acetylation reduces the overall affinity of Aβ for 
TBLE vesicles. As the steady state phase of fibril formation is reached for all conditions by 11 h 
of incubation (as determined by the ThT assay), the total fibril load has its largest contribution to 
the total PDA signal. In this regard, the magnitude of the PDA decreases with increasing 
acetylation in a similar fashion in comparison with the ThT assay. Lastly, at ~17 h the 
PDA/TBLE fluorescence signal associated with exposure to Aβ40 that had been not been treated 
NHSA or treated with 0.16 mM NHSA began to decrease instead of maintaining a plateaued 
maximum response. This drop-in signal eventually reaches that of the maximum response of 
other experimental conditions. Extensive fibrillization on lipid vesicles can lead to PDA vesicle 
instability leading to flocculation, and these two conditions were associated with the largest fibril 
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load. As a result, this likely reflects a loss in signal to the instability of the PDA/TBLE vesicles 
upon prolonged exposure to late-stage aggregates that alter the colloidal suspension. 
 
3.4 Discussion 
Understanding how individual amino acids of Aβ affect aggregation and peptide-membrane 
interactions are significant as it provides the possibility for focused, therapeutic targeting and 
may provide more effective treatment strategies. In this work, we explored the role of lysine’s 
cationic charge in the aggregation of Aβ40 in the presence and absence of membranes through its 
removal via acetylation. In summary, we demonstrate that 1) acetylation reduces the aggregation 
propensity of A40, eventually abolishing fibril formation; 2) acetylation impedes the formation 
of AOs; 3) under our experimental conditions, TBLE membranes slow A40 aggregation; 
however, acetylation of A40 promotes aggregation in the presence of TBLE compared to 
control; 4) acetylation of Aβ40 reduces the total A/membrane interaction; 5) the combination of 
acetylation and the presence of TBLE can promote the formation of annular aggregates of Aβ40. 
This work suggests that the A aggregation process (in both the presence and absence of lipid 
bilayers) is highly dependent on the charge state of lysine residues and that the A aggregation 
mechanism is unique on TBLE bilayers.  
Through increasing the concentration of NHSA, both K16 and K28 could be acetylated, 
but K16 was more readily acetylated. The preferential acetylation of K16 is consistent with 
structural studies of monomeric A demonstrating that K16 is solvent exposed while K28 is 
partially protected.22,64 Our experimental conditions created two regimes of A acetylation: one 
in which AcK16 predominated (0.16 mM and 0.32 mM NHSA) and the other in which the 
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abundance of AcK16 to AcK28 were similar (1.0 mM and 1.5 mM NHSA). As the complete 
absence of fibrils was observed only when K28 was appreciably acetylated, it is tempting to 
associate K28 acetylation with this observation. However, as substitution of either K16 or K28 
with alanine impacted A aggregation,23 it is likely that acetylation of both lysines plays a role in 
the observed inhibition of aggregation. There are plausible mechanisms associated with 
acetylation of either lysine.  K16 is associated with an amyloidogenic core sequence in A that 
plays a key role in fibril formation,9,10 and as a result, altering this region is likely to impact 
aggregation. There is precedent for such a notion as the Flemish mutation in Aβ, which changes 
an alanine to a glycine and is at the end of this amyloidogenic core sequence, significantly 
reduces the fate of Aβ fibrillization.65–67 Indeed, low concentration treatments of NHSA, when 
K28 is not appreciably acetylated, exhibited significant (although not absolute) reduction in fibril 
and oligomer formation. A potential mechanism for AcK16 inhibition of aggregation is provided 
by computational studies of Aβ42[K16A] demonstrating that the substitution of lysine results in a 
loss of intrapeptide contacts between the hydrophobic core and C-terminus of Aβ, therefore, 
reducing the propensity of β-sheet formation required for aggregation.68 With regard to K28, 
acetylation would disrupt its ability to participate in a salt bridge with D23 or E22. This salt 
bridge is associated with the turn region of a -hairpin observed in an Aβ fibril structure.17 The 
removal of K28’s cationic charge through acetylation would, therefore, destabilize A fibrils. 
Support for this mechanism can be seen in the success of a variety of A fibril inhibitors directly 
targeting this salt bridge.69–73 Furthermore, artificially creating the salt bridge between D23 and 
K28 via the addition of a lactam linker increases the rate of fibril formation by removing the 
entropic barrier imposed by the establishment of the salt bridge and effectively removing the lag-
phase.74 Changes in the net charge of Aβ40 from -3 to -4 or -5  may also play a role in impeding 
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fibril formation as increases in the solvation energy would reduce the strength of the 
hydrophobic collapse of Aβ that is associated with the initial stages of aggregation.75,76 
Beyond inhibiting fibril formation, acetylation of A reduces oligomerization. This 
finding appears to be in contradiction to the oligomerization of Aβ40[K16A], and Aβ40[K28A] 
which displayed similar oligomerization distributions to wild-type Aβ40.23 However, the 
detection limitations of the AFM analysis used here would not allow for the detection of the 
small oligomers (hexamers or smaller) observed by Sinha et al. With regard to the oligomers 
observable by AFM, these tend to be classified as high molecular weight (HMW) oligomers, and 
a number of toxic HMW AβOs  have been reported.77–80 The smaller, low molecular weight 
(LMW) AβOs tend to be less toxic or even benign compared with their HMW counterparts.77,79–
81 Our analysis suggests that even if acetylation does not alter the formation of LMW AβOs, the 
more toxically-relevant HMW oligomers are reduced by acetylation. With regards to potential 
mechanisms for this inhibition of AβO formation, molecular dynamics suggest that A 
oligomerization is governed through electrostatic interactions40 and that reducing electrostatic 
attraction promotes smaller ordered oligomers.41 Such a scenario is consistent with our 
observation that high levels of acetylation resulted in fewer and smaller AOs, as acetylation 
would reduce the electrostatic attraction between A peptides. 
The impact of acetylation on A aggregation suggests that targeting K16 and K28 can be 
an effective way to manipulate aggregation for potential therapeutic purposes. Indeed, there are 
several indications that such a strategy may be effective. A molecular tweezer, CRL01, that 
selectively binds to lysine side chains inhibits the formation of AOs and fibrils.82 Aspirin, 
which can act as an acetylating agent,83–85 can reduce the risk of AD86 and protects  HEK239 
3. Acetylation of Aβ40 alters aggregation in the presence and absence 
of lipid membranes  108 
cells against cytotoxicity associated with exposure to A fibrils.87  More broadly, aspirin reduces 
protein aggregation in several amyloid-based, neurodegenerative diseases,88,89 and this protection 
was directly linked to its ability to acetylate proteins in C. elegan models of Huntington's 
Disease and AD.88,90 However, aspirin’s ability to acetylate proteins is not lysine specific.91  
Lipid membrane environments have been shown to influence the aggregation of a number 
of amyloid-forming proteins29,61,92–96 and can even induce unique aggregation pathways.26,94 
Such a unique aggregation pathway would be consistent with our results with regard to A 
aggregation in the presence and absence of TBLE vesicles. While acetylation extended the lag 
phase A aggregation in the absence of TBLE vesicles, the opposite was observed in the 
presence of such vesicles, and A was able to form fibrils even after extensive acetylation 
associated with high concentration treatments of NHSA. Despite the shortened lag phase 
associated with acetylation of A in the presence of TBLE vesicles, the total fibril load was 
reduced, and polymorphic annular aggregates were observed. Collectively, this suggests that, in 
the presence of lipids, acetylation enhances the formation of the critical nucleus associated with 
initiating fibrillization but promotes secondary aggregation pathways. The enhanced nucleation 
could be related to enhanced diffusion along the membrane surface. That is, once bound to the 
lipid membrane, the removal of the cationic nature of lysine via acetylation could reduce the 
interaction with anionic head-groups, which may allow for freer diffusion of Aβ peptides along 
the membrane surface and increase the ability of peptides colliding and coalescing into a critical 
nucleus. A plausible scenario for the observed decrease in the slope of the growth phase, 
associated with the reduction in fibril elongation; and β-sheet load is that the inability to form a 
salt bridge between K28 and other residues increases the dissociation rate of monomers from the 
growing fibril ends relative to the association rate, resulting in an overall slower elongation. 
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aggregation in Alzheimer’s disease 
The proposed studies presented here are focused on gaining actionable information about 
preparatory conditions of Aβ for studying aggregation, developing new tools for research of 
AβO dynamics and structure, and exploring the role of a protective mutation on peptide-
membrane interactions. By extracting trends about Aβ preparatory protocols, insights can be 
gained into environmental changes that influence the self-assembly of Aβ, toxic mechanisms or 
promote more stable forms of oligomers. This information could be used for the advancement of 
BODIPY based oligomer specific dyes. The development of fluorescent small molecule oligomer 
specific dyes would allow for real-time tracking of AβOs formation, which is a current limitation 
in the field. The use of BODIPY oligomer specific dyes would also facilitate a high throughput 
methodology for screening therapeutics or stabilizing conditions for structural studies of AβOs. 
Also, we explore the idea of preserving isotope enriched Aβ in a heterogenic oligomer with a 
delayed transition towards fibril structures. The success of this technique could assist in the 
future development of more specific fluorescent dyes and provide knowledge of the three-
dimensional structure of AβOs, which is still currently unknown. Lastly, we contemplate a study 
designed to explore a protective mutation in AD and understand how its protective effects are 
tied to aggregation, morphology, and peptide-membrane interactions. Collectively these future 
projects are designed to address issues within the field and provide new tools and knowledge to 
advance the treatment of AD. 
 
 
4. Outlook: Future directions for advancing the understanding of Aβ  
aggregation in Alzheimer’s disease              118 
4.1 Introduction 
Alzheimer’s disease is a neurodegenerative disease that currently affects 5.4 million Americans. 
1 The classical neuropathology of AD is characterized as the formation of extracellular senile 
plaques and intercellular neurofibrillary tangles.2 A significant amount of effort has focused on 
the formation of senile plaques and earlier aggregate species of Aβ as the neurotoxic culprit, 
according to the amyloid cascade hypothesis.3,4 While there are indeed genetic links to AD, that 
cause early-onset AD, these are rare and only account for 5% of all AD-related cases.1 To date 
no genetic linkage or biomarkers have surfaced within the other percentage of the patient group, 
and the cause of AD still remains elusive.5 Currently, the largest risk factor for AD is aging, and 
95% of all cases occur within the elderly demographic.1 Therapeutic strategies and clinical trials 
have focused on both reducing the expression of Aβ and breaking up the existing aggregates 
within the brain.3 So far these efforts have mainly been unsuccessful,3,6–11 and the search for a 
common cause or mechanism of sAD is ongoing.  
Aβ is commonly post-translationally modified in the brain tissue and cerebrospinal fluid 
of AD patients,12 As hyperphosphorylation of tau is a known trigger for tau’s aggregation, it is 
likely that PTMs of Aβ trigger and modify amyloid formation. As an experimental methodology, 
PTMs represent valuable tools to probe the individual roles of specific amino acids on the self-
assembly and other physiologically relevant interactions of Aβ. 
One of the most well-known PTMs of Aβ is the oxidation of Met35 to its sulfoxide 
derivative. Due to the increase in reactive oxygen species associated with aging, oxidation of Aβ 
is elevated in patients of AD.13,14 In Chapter 2, the aim was to determine how changes in the 
oxidative environment associated with aging affected the aggregation of Aβ in the absence or 
presence of TBLE. This study demonstrated that exposing Aβ40 to H2O2 post-translationally 
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modified Met35 to its singly oxidized sulfoxide derivative, Aβ40Met35[O], as verified with MS 
and NMR. The percentage of Aβ40Met35[O] was found to be dependent on the H2O2 
concentration with increases in the H2O2 producing a higher percentage of Aβ40Met35[O]. This 
post-translational modification of methionine in the absence of lipids showed reductions in the 
slope of the growth phase, indicating a decrease in the elongation rate of fibril ends, and a 
reduction in the magnitude of fibril formation, but no significant changes in the lag phase time. 
AFM analysis of Aβ aggregation under increasing concentrations of H2O2 also revealed that the 
oligomerization of Aβ was not inhibited, but structural transitions towards parallel β-sheet 
structures were inhibited. Further evidence from the AFM also demonstrated the presence of 
polymorphic fibrils in the presence of 6.0 mM H2O2. However, when kinetic assays were 
performed in the presence of membranes, Aβ40 exposed to higher concentrations of H2O2 
correlated with less peptide-membrane interactions, and it was determined that the oxidation 
state of total brain lipid (TBLE) vesicles largely modulated the peptide-membrane interaction.  
Acetylation of Aβ is not a physiologically observed PTM of Aβ; however, the ability to 
chemically modify lysine makes it an attractive target for studying the role of that cationic 
character of lysine in A aggregation. Aβ contains two lysine residues, K16 and K28, both of 
which are known to form intermolecular salt bridges in A amyloid structures.15–18 In Chapter 3, 
we sought to determine how the removal of lysine’s cationic charge through acetylation would 
alter Aβ40 aggregation in the presence and absence of lipid membranes. Here we demonstrated 
that acetylation of Aβ readily occurs at the more solvent exposed K1619 while K28 is acetylated 
at higher concentrations of NHSA. The acetylation of Aβ was shown to increase the lag-phase of 
Aβ40 while also reducing the magnitude of fibril formation to the point that at 1.0 mM NHSA 
and 1.5 mM NHSA fibril formation was completely inhibited. AFM analysis of acetylated Aβ40 
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also showed a marked reduction in the number of oligomers formed, demonstrating that fibril 
formation and oligomerization are both inhibited by acetylation. Morphological height analysis 
of Aβ fibrils formed under milder acetylating conditions indicated the absence of any 
polymorphisms suggesting fibril inhibition may be impart due to the prevention of Aβ to form 
salt bridges and participate in fibril formation. However, the presence of TBLE lipid vesicles 
promoted the aggregation of acetylated forms of Aβ40 with a decreased lag-phase and extent of 
fibril formation for all acetylating concentrations. The reduction in the lag-phase compared to the 
control of Aβ40 was found to arise from the decrease in the total Aβ-membrane interactions as 
assessed by PDA. Lastly, the presence of TBLE under NHSA concentrations of 1.0 mM and 1.5 
mM NHSA promoted the formation of a distinct annular aggregate species. Collectively the 
work of Chapter 3, suggested that the oligomerization and fibril formation of Aβ is highly 
dependent on the cationic charge of lysines and that under the influence of membrane surfaces 
the mechanism of Aβ aggregation is alter. 
 As there is still no treatment for AD, continued research into the root causes of this 
disease are warranted. Here, several issues still facing the field will be discussed in context of the 
experimental results presented in this dissertation. These persisting issues in the field include: 1) 
the inconsistency of Aβ disaggregation and preparation protocols that complicate analysis across 
literature reports; 2) the inability to monitor oligomer formation in real-time in a high throughput 
manner; and 3) unraveling the structure of oligomeric Aβ species.  
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4.2 Meta-analysis of Aβ sample preparation and experimental outcomes 
Preparation protocols of Aβ typically involves three steps; disaggregation, reconstitution, 
and dilution into buffering system, but the choice in the protocol used can alter experimental 
outcomes.20 While several methods for the disaggregation of Aβ exists reproducibility across 
labs, manufactures, and batches of Aβ is poor.21,22 To overcome this many laboratories use 
hydrogen bond disrupting alcohols, strong acids, strong bases, or organic solvents such as 
hexafluoroisopropanol (HFIP), trifluoroacetic acid (TFA), ammonia, or dimethyl sulfoxide 
(DMSO). Next, Aβ is reconstituted in a secondary step before being diluted into a buffer. The 
disaggregation and solubilization protocols vary from laboratory to laboratory and complicate 
the ability to compare results.23,24 These differences in experimental outcomes can include 
changes in kinetic measurements,25 morphology,26,27 secondary structural transitions,28 
membrane interactions,38 and toxicity.25,28 Ultimately, the irreproducibility of results create 
controversy within the field, and attempts to standardize a methodology will not be applicable to 
all experiments.29  
In Chapter 2 Aβ was disaggregated with ammonium hydroxide and reconstituted with a 
60 mM NaOH solution to obtain a monomeric stock of Aβ40. This was a deviation from the 
typical A preparation protocol that had been historically used in the Legleiter laboratory, which 
was based on the ‘Stine prep’ (disaggregation of Aβ with HFIP and solubilizing in DMSO).30 As 
DMSO is a radical quencher of H2O2, the 'Stine prep' was not suitable for our experiments. The 
‘Stine prep’ produces fibrils of ~6 nm thick and exhibited accelerated fibril formation in the 
presence of TBLE; whereas, the protocol used in Chapter 2 and 3 resulted in fibrils that where ~3 
nm in width, and reduced rates of fibril formation in the presence of TBLE. Furthermore, the lag 
phase of control A aggregation reactions increased in studies reported in Chapter 3 compared to 
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those reported in Chapter 2. This change was the result in differences in the synthesized Aβ 
peptides associated with different suppliers. The Aβ40 in Chapter 3 had a counterion of TFA as 
opposed to NH4
+ in Chapter 2. Ultimately the problem lies in the lack of knowledge of how 
preparation protocols of Aβ influences results. Understanding how changes in the preparation of 
Aβ alters aggregation could provide insights into how multiple conditions affect aggregation and 
could allow for experimental designs that would probe variations in aggregation.  
A possible solution to this issue could come in the form of a combinational approach 
utilizing data mining and establishing a convenient method for the field to compare experimental 
results.  To discover connections between the varied preparations of Aβ and provide the ability to 
directly compare results across laboratories, a two-stage approach could be taken. The first stage, 
acquisition of data, would require the entry of research findings into a database that would 
catalog entries based on the preparatory steps used, kinetic parameters, toxicity results, structural 
observations, etc. Databases could be built by extracting relevant research articles from journal 
services and incorporating pdf into our own database. The biggest hurdle to overcome would be 
getting copyright permission from journal services as the methods sections containing Aβ 
preparation is not freely available like abstracts, however many journals have been amenable to 
such studies recently. In addition, data mining could then be performed to search our databases 
to look for similarities in results and trends that may not be readily observable between across 
disciplines. This may provide useful insights into the aggregation differences between expressed 
or synthetic Aβ and HFIP or alkaline disaggregated Aβ. 
The second stage would be to make the data freely available to scientist via a web-based 
interface. This web portal would allow for scientist to search based on a broad range of 
experimental outcomes, preparations, cellular models, etc. In addition to providing this service, 
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other scientist would be freely able to upload their results with links to their research to grow the 
datasets. The entries from the point of view of the scientist would be convenient/simple and 
would be comprised of a simple questionnaire that allows the researcher to enter in the 
disaggregation, reconstitution, and miscellaneous protocols used for their experiment. This 
would be beneficial over requiring the uploading of raw data into which can be time-consuming.  
Lastly, once this information becomes more available and widely used the expansion of 
the database could include other amyloidogenic proteins such as α-synuclein and Huntingtin, 
providing a more significant impact beyond that of just Alzheimer’s disease. Many scientific 
databases have proven useful to the scientific community such as the Spectral Database for 
Organic Compounds and the Protein Data Bank. Ultimately, it is with this aggregation of data 
into a centralized location that would allow for the extraction of information and trends among 
Aβ preparations that may provide actionable information that could further be experimentally 
tested in the laboratory. 
4.3 Real-Time tracking of Aβ oligomerization 
Environmental conditions, preparation, and the presence of membrane surfaces all affect 
the oligomerization of Aβ. Atomic force microscopy (AFM) and electron microscopy (EM) 
provide the capability to track AβO formation. In particular, AFM is a particularly useful 
technique in studying AβO formation and morphology31–41 as it can be operate at physiologically 
relevant conditions. Immunohistostaining of toxic AβOs also appear to react with oligomer-
specific antibodies like A11 (generic for amyloid oligomers in general).42 In Chapter 2 and 3 we 
used the state of the art technique of AFM to track oligomer formation, but our methods and others 
are limited by their ability to finely resolve the kinetics of AβO formation. Therefore, new tools 
that can allow us to track the kinetics of AβOs in real-time would fill a current gap in 
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understanding the dynamics of oligomer formation. A promising method for achieving real-time 
tracking of AβOs is the use of BODIPY base derivatives. 
Specifically in Chapter 3 AFM was also used to visualize the inhibition of AβO 
formation when Aβ was acetylated, however our results differed from Sinha et al who observed 
the oligomerization of Aβ40[K16A], and Aβ40[K28A] which displayed similar oligomerization 
distributions to wild-type Aβ40.43 One possible reason for the discrepancy comes from detection 
limitations of the AFM which does not allow for the detection of oligomers smaller then 
hexamers, as observed by Sinha et al. In addition, using cross-linking methods, e.g. PICUP, or 
imaging with AFM limits the speed at which one can assess the dynamics of AβO formation. In 
developing a tool that would allow for the detection of LMW and HMW AβOs in real-time 
would be a vitally useful tool to all scientist studying AβO formation. A promising strategy to 
develop this capability is using BODIPY based fluorescent dye that are selective for AβOs. 
Several straightforward spectroscopic assays are well-established to track formation and 
kinetic parameters of fibrils (e.g., thioflavin-T), but methods to easily track AβO formation have 
been lacking. Recently, the use of 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene (BODIPY) dyes 
have been utilized to detect the AβOs in vitro fluorescently.44,45 These BODIPY fluorescent 
probes have high quantum yields with the capability of selectively binding to AβOs.46  
Importantly, increases and decreases in the “BD-Oligo” dye fluorescence also correlated with 
increasing and decreasing intensities of the A11 antibody (generic for amyloid oligomers in 
general staining), directly relating this signal to an established method to detect AβOs 67 In 
addition, the BD-Oligo dye can be used in parallel with ThT assays that detect fibril formation, 
allowing for the direct investigation of the correlation between oligomer and fibril formation.67 
Rational design of BODIPY based dyes also allows for the the ability to selectivly target 
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different aggregates of Aβ or other amyloidgenic protiens. The design of a BODIPY-base dye 
(BAP-1) was successful in facilitating the direct visualization of Aβ plaques in transgenic mice,46 
and rational modifications of BAP-1 also allowed for near-infrared selective detection of tau 
neurofibrillary tangles.47 The ability to rationally modify BODIPY dyes for fluorescent detection 
of specific aggregate species, the tunability of their spectroscopic properties, and their 
insensitivity to solvent and pH changes have made BODIPY dyes a recently promising avenue 
for high throughput studies. 
Ultimately, the applications of a BODIPY dye derivative that is selective for AβOs are 
broad. BODIPY could replace expensive oligomeric antibodies providing the ability to stain gels, 
dot blots, slot blots, and tissue samples cheaply. BODIPY can also be applicable to studying the 
dynamics of AβO formation which is limited in AFM and photo-cross-linking studies presented 
in Chapter 2, 3, and the work by Sinha et al. Modification of BODIPY dye derivatives may also 
prove useful in the application of distinguishing LMW and HMW AβOs, though the failure to 
selectively distinguish these species would instead also provide an experimental overlap between 
HMW AβO measured in AFM studies, as presented in Chapter 2 and 3, and photo-cross-linking 
studies which focus more on LMW. Additionally, spectroscopic techniques such as super-
resolution microscopy and total internal reflection fluorescence microscope can utilized 
BODIPY probes to resolve accumulations of AβOs at the membrane interface of cells through 
FRET pairing or track the dynamics of AβO aggregation, transitions, and possible even 
trafficking and cerebral imaging in biological systems. Broadly, the development of a fluorescent 
molecule that selectively binds AβO oligomers would be applicable to the discovering a 
fluorescent molecule like ThT which has proven to be a gold-standard in the development of 
assess Aβ fibril formation, dynamics, and aggregation pathways.  
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4.4 Using reverse-phase micelles for structural studies of oligomeric Aβ 
 Enormous efforts have been expended in identifying the most toxic/disease-relevant AO 
species and the relevant underlying structure.48–50 This is a daunting endeavor due to the transient 
nature and extensive heterogeneity associated with AOs.51–53 It is possible that different AβO 
species may activate different deleterious changes associated with AD;48–50 however, there may 
also be relatively benign AO species or even experimental artifacts.24,51,54 Unraveling the 
physiological activity of AβOs may require separate analysis of these different species, which are 
altered by preparatory protocols.32 In practice performing varied preparatory protocols can yield 
changes in rates of aggregation, polymorphism, and toxicity of AβOs.25,27,32  
 To facilitate structure/activity analysis, significant efforts have been made to obtain 
structural details of AβOs using a variety of methods (Table 4.1). This is required to fully 
elucidate the modes of interaction of AβOs with other, fluorescent molecules e.g. BODIPY,  
biomolecules, and related toxic mechanisms.55–60 Structural characterization of specific AOs is 
challenging due to their transient nature and heterogeneity. AβOs can exhibit conformational 
plasticity that can be heavily influenced by environmental factors, further complicating such 
analysis. 
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Table 4.1. Methods used for analyzing AβOs. 
Technique Features of AβOs Obtained 
Atomic Force Microscopy (AFM) Morphology, population distributions 
Electron Microscopy (EM) Morphology, population distributions 
Ion-Mobility Mass Spectrometry 
(IM-MS) 
Secondary structure, multimeric configurations 
Nuclear Magnetic Resonance 2D 
(NMR) 
Secondary structure, multimeric configurations, atomic 
resolution structure 
Electron Paramagnetic Resonance 
(EPR) 
Secondary structure, multimeric configurations, atomic 
resolution structure 
Powder X-ray Diffraction (PXRD) Atomic resolution structure 
Small Angle X-ray Scattering 
(SAXS) 
Atomic resolution structure 
Single Crystal X-ray Diffraction 
(SCXD) 
Atomic resolution structure 
SDS-Page Size distribution of multimers 
 
 In Chapter 2 we observed that increasing the ratio of oxidized to unoxidized Aβ had the 
effect of delaying the oligomer transition to protofibril or fibril species. This transition was 
roughly delayed by 3 h (Figure 2.3B). This 3 h window would provide ample time to perform 
other separation steps that would enable the isolation of AβOs. This isolation of AβO in the 
absence of cross-linking and covalent linkages is more advantageous as it is less likely to induce 
peptide structural modifications. Capitalizing on this observation, it may be possible to use a 
mixture of oxidized and unoxidized Aβ to delay the oligomer transition to fibrils and further 
encapsulate them through reverse phase micelles (RM) to structurally study Aβ within an 
oligomeric aggregate.  
First, determining the ideal ratio of Aβ40 to Aβ40Met[O] would be essential in optimizing 
the extension of the AβO phase. Once established, isotope enriched Aβ40 could be mixed with 
Aβ40Met[O] in a buffer to produce oligomeric aggregates with extended stability. While AOs 
are often heterogeneous in size, additional separation steps may be required to obtain more 
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homogenous samples that are amenable to structural analysis.  This can be accomplished by size-
exclusion chromatography (SEC) or a sucrose gradient and centrifugation. However, this may 
dilute samples below concentrations required for structural analysis, and AβOs, given time 
beyond the stabilizing window provided by oxidation, may further associate producing larger 
aggregates. Both issues could be solved via encapsulating the AβOs in RMs, which would 
prevent further aggregation and allow for concentrating samples. To encapsulate AβOs within 
our aqueous solution we first need create an emulsion of hexane and H2O to promote the 
formation of sodium bis(2-ethylhexyl)sulfosuccinate (AOT) RMs.61,62 After encapsulation 
centrifugation would be utilized to concentrate samples and be resuspended RM-AβOs in hexane 
at the desired concentration. The three-dimensional structure of Aβ within the AβO structure 
could then be determined through solution-state NMR. Previously, encapsulation of monomeric 
Aβ for structural studies and solution NMR structures of Aβ in water-micelle environments have 
been effective in determining structural elements of Aβ.63,64 By suspending the unoxidized 
isotope label Aβ40 within an AβO structure we might be able to determine the structure of Aβ 
within an oligomer. 
Due to the lack of structural information of AβOs, insights into their structure would be 
paramount. This would allow for a more rational design of AβO fluorescent probes e.g. BODIPY 
which would allow for high throughput determination of oligomer dynamics. Additionally, the 
3D structure of AβOs would also benefits computational chemistry by providing a relevant 
starting point for simulations overall reducing the requirement of computational resources 
required instead of starting with monomeric forms of Aβ. Finally, structural knowledge of AβOs 
would also allow for the development of more effective small molecule or antibody therapeutics 
helping to provide a treatment option where none are currently available. 
4. Outlook: Future directions for advancing the understanding of Aβ  
aggregation in Alzheimer’s disease              129 
4.5 Protective Mutations 
In Chapter 3 we acetylated K16 and K28 to explore the role of lysine’s electrostatic 
interactions that are associated with aggregation and membrane binding. We determined that in 
the absence of lysine’s cationic charge oligomerization and fibrillization were inhibited, and 
while membrane interactions were reduced the membrane facilitated the formation of the critical 
nucleus promoting fibril formation alongside promoting secondary aggregation pathways. 
Initially we would have expected that removing the cationic character of lysine would diminish 
Aβ-membrane affinity. Instead other regions of Aβ, specifically the hydrophilic N-terminus, may 
also be involve in the peptide-membrane interaction. However, the role of the N-terminal region 
of Aβ in oligomerization and polymorphism has remained unexplored largely due to its 
unstructured nature.63,65 Recently, a structural study has propose that the N-terminus is 
responsible for stabilizing the central hydrophobic core (CHC) in its monomeric state,66 and may 
prevent the hydrophobic collapse of the CHC to the C-terminus which may initiate the 
aggregation process. More recently, the charge state of the N-terminal region is found to regulate 
Aβ-membrane interactions with the removal of anionic glutamic acid (E11) and cationic lysine’s 
(K16) exhibiting the slowest deposition rates on POPC bilayer.67 
Recently, a familial mutation in Aβ, A2T, has been discovered and is the only mutation 
known to exert a protective effect in Alzheimer’s disease. Also, the A2V mutation has been 
discovered but instead results in early-onset Alzheimer’s disease. When mixing N-terminal 
fragments of the 1-7 A2T variant with Aβ fibrillization and cytotoxicity of Aβ was reduced, 
however when repeated with the addition of the A2V mutation the opposite effect was 
observed.68 Furthermore, AFM imaging of Aβ40, Aβ40(A2T), and Aβ40(A2V) fibrils in the 
absence of membranes have demonstrated the presence of polymorphic fibrils,69 and in the 
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presence of a zwitterionic membrane, A2T fibril formation is increased compared to wild-type 
Aβ.70 From our experiments in Chapter 3 and these recent findings, it is possible that the polar 
A2T mutation will result in reduced oligomerization; whereas, the hydrophobic A2V will 
increase oligomerization. In addition, the A2T mutation should exhibit increased association 
with the membrane while disallowing the insertion of Aβ into the membrane; the A2V mutation 
should have the opposite effect due to the hydrophobic nature of valine. This could be tested 
experimentally using the same methods and techniques used in Chapters 2 and 3. Ultimately, this 
would clarify how changes in the N-terminus of Aβ effect the oligomerization and membrane 
binding of Aβ. If the more polar A2T mutant exhibited greater oligomerization and membrane 
binding but reduced membrane disruption this would show that the toxic mechanism of the Aβ-
membrane interaction is not just connected with Aβ’s association to the membrane but also 
requires the insertion into the membrane, a finding that would mirror toxicity studies of oxidized 
Aβ and results of Chapter 2.71–73  
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